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Cell processing lies at the heart of modern medicine. While in the past, the 
treatment of diseases such as cancer was based mostly on the cancer’s tissue of origin and 
histological classification, today these decisions are also informed by detailed functional 
and molecular characterization of a patient’s own cancer cells, a practice commonly 
referred to as ‘personalized medicine’. Treatments for cancer and other diseases have also 
recently evolved to use manufactured cell therapies derived from the patient’s own tissue. 
For example, recent therapies for cancers such as leukemia reprogram immune cells 
harvested from a patient to target malignant cells, and regenerative medicine techniques 
seek to manufacture patient-derived cells capable of replacing tissue lost due to injury or 
inherited degenerative conditions. 
While these new therapies are targeted at a wide variety of different conditions, 
they all share a dependence on efficient processing of patient cells, which often takes the 
form of either cell sorting or transfection. For example, for personalized medicine 
techniques to be effective, clinicians must have access to a patient’s malignant cells. While 
cells from a solid tumor can be harvested via biopsy, depending on where the tumor is in 
the body, performing this type of biopsy can be an invasive procedure. One alternative is a 
‘liquid biopsy’, where instead of removing a piece of a patient’s primary tumor, a liquid 
sample such as blood or abdominal fluid is taken from the patient. While this type of 
procedure is generally significantly less invasive than a traditional biopsy, it does not yield 
a pure population of the patient’s malignant cells. These cells are often a minority 
population in these liquid samples, surrounded by contaminating, non-malignant cells such 
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as blood and immune cells. To increase the sensitivity of any molecular or functional assays 
that caregivers plan to perform on these harvested cells, techniques are needed to sort the 
cancer cells needed for analysis from contaminating healthy cells. 
Cell sorting is also required for manufacture of regenerative medicines. One such 
application is induced pluripotent stem cell (iPSC) derived autologous cell replacement 
therapies. In this approach, cells (usually fibroblasts harvested from a skin biopsy) are 
transformed into iPSCs through forced expression of a series of transcription factors. These 
iPSCs are then differentiated into cells capable of replacing tissue in the patient that has 
been lost due to injury or inherited degenerative disease. For example, in the case of 
inherited degenerative blindness one possible treatment is the implantation of 
manufactured patient-derived photoreceptors to replace those that the patient has lost over 
the course of their disease. While these approaches hold great promise, one issue with 
current cell manufacturing techniques is the limited control that scientists have over the 
lineage of differentiated cells. For instance, modern protocols for the generation of 
photoreceptor cells from patient derived iPSCs do not generate pure populations of 
photoreceptors. Instead, all of the cell types which make up the retina are generated, usually 
organized very similarly to the way they are in vivo. Given that not all of these cells are 
desired for transplantation, some mechanism is needed to separate the potent cells desired 
for transplant from the contaminating cells. 
While mature cell sorting technologies exist, they have limitations that make them 
less than ideal for personalized and regenerative medicine. The two most mature 
technologies are known as fluorescence activated cell sorting (FACS) and magnetic 
activated cell sorting (MACS). In both techniques, labels are attached to cells using 
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antibodies that recognize markers present on cell surfaces. In FACS, these antibodies are 
conjugated to fluorophores, allowing the presence of the antibodies to be detected on the 
surfaces of the cells using optical techniques. Sorting is then accomplished with a fluidic 
system that passes cells one at a time through a series of lasers and photodetectors, after 
which the cells are deposited into different collection tubes based on the presence or 
absence of several different markers. The MACS approach, on the other hand, uses 
antibodies conjugated to paramagnetic beads. After labeling cells with these beads, tagged 
cells can be separated from untagged cells using a permanent magnet. 
While both of these techniques can be very specific and operate at high throughput, 
their reliance on antibody labels makes them difficult to apply in some personalized and 
regenerative medicine applications. For example, in cancer applications there is often no 
unique marker present on the surface of cancer cells, and any markers that do exist can 
differ dramatically from patient to patient. Further, even if the required markers do exist, 
it is possible that conjugating an antibody to cell surface receptors could alter the behavior 
of cells in downstream functional assays. Similarly, in regenerative medicine applications 
where unique cell surface markers exist, conjugation of antibodies to cells destined for 
implantation into a patient constitutes a significant safety concern. 
To address these concerns, ‘label-free’ sorting techniques (i.e. techniques that do 
not require antibody labels) are required. In recent years, this need has spurred the 
development of several such label-free techniques, many of which are implemented as 
microfluidic chips. While there are label-free techniques that are not based on a 
microfluidic platform, the microfluidic approach offers several key advantages. First, 
microfluidic devices based on standard microfabrication techniques can be manufactured 
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very cheaply, meaning that these devices can be designed as single-use disposables. In 
addition to making these approaches very inexpensive to incorporate into existing cell 
manufacturing workflows, there is also a significant safety benefit, given that the use of 
disposables drastically reduces the risk of cross-contaminating cells being manufactured 
for one patient with those destined for another. In addition, given the very small size of 
these devices, they are amenable to massive parallelization. This allows engineers and 
scientists developing these platforms to optimize the design at relatively small scale and 
then dramatically increase throughput once the design of the system has been optimized. 
Another form of cell processing often required for the manufacture of cell therapies 
is transfection, the delivery of cargo into cells. For instance, when manufacturing cell 
therapies for the treatment of inherited blindness, the genetic defect which originally 
caused the onset of disease must be corrected in any cells destined for transplant to prevent 
the therapeutic cells from suffering the same fate as the patient’s native cells. Similarly, in 
immune therapies for cancer, macromolecules must be delivered to the therapeutic cells in 
order to target them against the patient’s cancer. Similarly to cell sorting, several 
techniques for cell transfection have been developed and commercialized, but these ‘gold-
standard’ approaches have limitations which restrict their usefulness to manufacturing cell 
therapies. Current ‘gold-standard’ approaches include viral transfection, electroporation 
and lipofection. 
Viral transduction is a robust technique, capable of very high transfection 
efficiency. In this technique, nucleic acid sequences that encode proteins that alter cell 
behavior when expressed are packaged into viruses, which then inject their payload into 
cells. While this approach is very well characterized and efficient, it suffers from several 
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important drawbacks. First, packaging the desired message into viruses is not a simple 
process, and requires specialized equipment and highly trained personnel. Second, when 
these viruses are engineered to incorporate their payload into host cells, there is a risk of 
mutagenesis, which could cause transformed cells to form tumors. Finally, there is an upper 
limit on the size of constructs that can be packaged into viral vectors. This limit is smaller 
than many therapeutically relevant genes. For instance, USH2A, mutations in which are 
responsible for multiple forms of inherited blindness, is too large to be packaged into the 
most clinically favorable viruses. 
Non-viral techniques, such as lipofection and electroporation, are not subject to 
these packaging limitations, but have their own drawbacks. First, while it is possible to use 
these techniques to deliver constructs that cannot be packaged into viruses, the delivery 
efficiency of these techniques drops significantly with increasing payload size. Therefore, 
while it is possible to use these systems to deliver large genes such as USH2A, these 
approaches have very low transfection efficiency for these large payloads. In addition, both 
of these techniques require the use of proprietary reagents which pose a significant 
regulatory burden in terms of proving their safety for use in human subjects. 
Due to these drawbacks, the research community has recently developed reagent-
free microfluidic transfection platforms that accomplish delivery into cells through 
mechanical perturbation of the cells. In addition to evading the regulatory burdens 
associated with lipofection and electroporation, these platforms are also not subject to the 
packaging size limitation posed by viruses. Further, as discussed above with respect to 
microfluidic sorting platforms these approaches can be implemented as low-cost 
disposable chips which is desirable in terms of safety and allows easy incorporation into 
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existing cell manufacturing pipelines without requiring the purchase of large, expensive 
equipment that must be thoroughly decontaminated after each use. New transfection 
platforms are needed that exhibit high transfection efficiency that is not a function of 
construct size for correcting disease-causing mutations in large genes in cells destined for 
transplant into a patient. 
In this thesis, I will detail the development of microfluidic platforms capable of 
solving significant issues in current cell processing pipelines for personalized and 
regenerative medicine applications. After a review of methods currently being developed 
by the community to address the issues in ‘gold-standard’ techniques, I will present my 
recent intellectual and technological contributions to this effort. First, I will describe my 
development of a label-free, microfluidic approach for the isolation of metastatic cancer 
cells from liquid biopsies of ovarian cancer patients, demonstrating how this technology 
can enhance both diagnostics and prognostics in cancer treatment. Next, I will demonstrate 
how microfluidics can be used to separate dissociated human retina into therapeutically 
relevant subpopulations as an example of how these techniques can be used to separate 
cells with a desired phenotype from cells of related lineages to enhance the potency of iPSC 
derived cell therapies. Finally, I will present my work on the development of microfluidic 
methodologies to enable high-efficiency, reagent-free delivery of macromolecules to iPSC 
cells. Taken together, this work demonstrates the promise of microfluidics to revolutionize 
the fields of cancer treatment, cell manufacturing and regenerative medicine. 
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CHAPTER 1. INTRODUCTION 
Today, many therapeutic approaches rely on the efficient processing of patient cells. 
Personalized medicine, which promises to revolutionize oncologic care and regenerative 
medicine to treat many diverse conditions, depends on the processing of a patient's own 
cells using a variety of techniques. For most cancers, gathering cells via biopsy is an 
invasive process, meaning it is often preferable to isolate a patient’s metastatic cells from 
samples which can be obtained relatively non-invasively such as blood or other liquid 
patient samples. But in many liquid biopsies of patient cell samples, such as from 
abdominal ascites or pulmonary effusions, the cells of interest generally make up a small 
percentage of the heterogeneous cell population present in the sample causing high rates 
of false negative specimens. Therefore, the first step in most personalized medicine 
approaches is the isolation of the cells of interest from some mixed population of normal 
and oncologic cells. In addition, the last step in many cell therapies is the isolation of potent 
cells required for treatment from contaminating cells. This can be performed using a variety 
of approaches, including flow activated cell sorting (FACS), magnetic activated cell sorting 
(MACS), as well as new microfluidic approaches including ours, in which high-throughput 
mechanical manipulation is used to sort cells by their mechanical properties.  
While MACS and FACS can be quite selective, they generally require the cells of interest 
to express some type of unique surface protein that can be tagged using antibodies, which 
increase the cost and complexity of the assay. In some cases, these markers are not 
expressed solely on the cells of interest, making these approaches much harder to apply 
successfully to obtain sufficient purity. Novel label-free microfluidic methods, including 
 2 
our platform, can allow us to sort based on cellular mechanical properties that may be 
sufficiently distinct to the target cells to avoid relying on the presence of cell surface 
markers. Label free approaches would be ideal to isolate tumor cells with unreliable or 
absent cell surface antigens, such as metastatic ovarian cancer cells from liquid abdominal 
ascites samples. 
In regenerative medicine applications, since therapeutic stem cells are transplanted into 
patients to regenerate tissue, an additional safety concern is at stake in separations. In 
therapeutic cell engineering, all reagents applied to the cells must be guaranteed to be safe 
in order to gain regulatory approval. As antibodies used for labeling are derived from 
animal sources, they pose an additional risk and regulatory burden. Therefore, label free 
sorting of the therapeutic cells from a heterogeneous culture is desirable. In a project 
focused on cell replacement-based treatment of inherited retinal degenerative blindness, 
we generate retinal photoreceptor cells destined for retinal transplantation by 
differentiating patient-derived induced pluripotent stem cells (iPSCs). Retinal 
differentiation protocols, while very effective in generating photoreceptor cells, also 
produce contaminating retinal cell types such as retinal pigmented epithelium, retinal 
ganglion and bipolar interneurons, which are less useful therapeutically and should be 
removed prior to transplantation. Sorting these cells using gold-standard approaches such 
as FACS and MACS, which as indicated above rely upon the use of antibodies, would 
drastically increase cell manufacturing labor, patient risk and the regulatory burden of the 
therapy. In addition, conjugating antibodies to the cells destined for transplant could 
compromise the effectiveness of the treatment. 
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In addition to its utility for cell sorting, we further have discovered that high-throughput 
mechanical manipulation of cells, specifically rapid, repeated cellular compression, can 
facilitate delivery of large macromolecules and other therapies into the cell interior [1], [2]. 
For this platform, delivery is accomplished via convective, rather than diffusive transport, 
meaning that delivery efficiency is not a strong function of the size of the construct being 
delivered into the cells. The delivery of large nucleic acids provides an ideal solution to the 
challenge of CRISPR-based correction of genetic defects that cause inherited eye disease. 
Multicistronic CRISPR constructs, which contain guide RNAs, homology-directed repair 
(HDR) templates and antibiotic selection cassettes, can be well over 14,000 base pairs in 
length, resulting in transfection efficiencies of lower than 1% when using lipofectamine. 
Using our new discovery of convective transport of genetic cargo, mediated by a 
microfluidics-based approach, we find that transfection can be achieved without the use of 
chemical reagents which will result in safer treatments and lower regulatory burden. 
The long-term goal of this research is to enable high-throughput purely mechanical 
processing of cells for therapeutic applications. To achieve this goal, I will leverage a 
microfluidic platform which applies repeated, high speed compressions to single cells in 
the pursuit of three specific aims, a summary of which is presented in Figure 1. 
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Figure 1. Overview of specific aims. Each aim addresses a need in modern cell 
manufacturing workflows (top). Aim one demonstrates isolation of cancer cells from 
patient liquid biopsies. In aim two, I demonstrate how microfluidics can be used to sort 
photoreceptors from dissociated human retina, as a model for how mixed cell populations 
can be sorted to increase the potency of manufactured cell therapies. In aim three I explore 
how microfluidics could be used to make transfection more efficient in cell engineering 
applications. 
1.1 Specific Aim 1: Isolation of metastatic ovarian cancer cells from primary 
abdominal ascites samples. 
1.1.1 Summary 
A microfluidic sorting device was designed and tested to isolate metastatic ovarian cancer 
cells from the abdominal ascites of patients with advanced ovarian cancer. In order to 
optimize the device’s sensitivity to the differences between cells with differing levels of 
malignancy and metastatic potential, we first flowed pure populations of representative cell 
lines through the device and assess the trajectory of each cell type using high-speed 
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microscopy. We then proceeded to optimize the sorting of a malignant cell line from a non-
malignant cell line to determine device parameters (constriction size) and experimental 
conditions (flow rate) that allow for the most specific sorting of cells based upon their 
metastatic potential. Finally, we sorted the heterogeneous cell population present in the 
abdominal ascites of patients with late stage ovarian cancer. Our ability to sort these cells 
was assessed by examining the rate of P53 mutations present in the cell populations as well 
as by staining the sorted populations for TG2, overexpression of which is associated with 
malignancy in ovarian cancer. 
1.1.2 Significance 
In this aim, we demonstrate the first ever label-free microfluidic enrichment of primary 
ovarian cancer cells from patient ascites samples. Our success in this effort shows that 
label-free microfluidic cell sorting has the potential to increase the sensitivity of functional 
and molecular characterization of cancer cells for personalized medicine applications by 
enabling the preparation of purified samples of cancer cells from liquid biopsies without 
depending on cell surface markers. 
1.2 Specific Aim 2: Sort photoreceptor cells from a heterogenous population of 
human retinal cells without relying on the use of cell surface antigens and 
antibodies. 
1.2.1 Summary 
To optimize sensitivity to the biomechanical differences between cell types present in 
human retina we performed the first mechanical characterization of two representative 
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retinal cell lines, a retinal pigmented epithelial cell line (ARPE-19) and a human iPSC 
derived photoreceptor precursor cell line (iPSC-PPC). After discovering that the two cell 
lines representative of important retinal cell types were mechanically distinct, we 
proceeded to sort the two cell lines and assessed enrichment via flow cytometry. Finally, 
we used the optimized microfluidic device to sort dissociated postmortem human retinal 
cells. Sorting performance was assessed using qPCR to demonstrate enrichment of 
different retinal cell subpopulations at different outlets of the microfluidic device. 
1.2.2 Significance 
In this aim, we demonstrate the first-ever label-free microfluidic fractionation of 
dissociated human retina into biologically meaningful subpopulations. This success 
indicates that label-free microfluidic cell sorting could be used to isolate photoreceptors 
from the mixed population of cells produced by modern iPSC retinal differentiation 
protocols. Such label-free isolation of photoreceptors has the promise to increase the 
potency of cell therapies for inherited retinal degenerative blindness without the use of 
animal-derived antibodies and other reagents that could compromise the safety of the 
treatment. 
1.3 Specific Aim 3: Use microfluidics to deliver large functional constructs to 
patient derived iPSCs in a one-step mechanical process 
1.3.1 Summary 
To enable the design of a microfluidic transfection platform for the delivery of 
multicistronic plasmids encoding humanized Cas-9, guide RNAs and homology-dependent 
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repair (HDR) templates for correction of mutations in iPSCs generated from patients with 
inherited retinal degenerative blindness microscopic size analysis was carried out. Based 
on this data we designed devices with a range of gap sizes and demonstrated delivery of a 
large multicistronic CRISPR/Cas9 construct that was comparable to the gold-standard 
lipofectamine. To enhance transfection efficiency further, an extensive characterization of 
the size of patient-derived iPSCs under a variety of conditions was carried out on cells in 
suspension. In addition to revealing which factors need to be controlled in order to 
minimize batch-to-batch variability in iPSC size, this work revealed that a significant 
degree of heterogeneity in terms of size exists in every population of iPSCs measured in 
this study. In order to enable high-efficiency transfection of these heterogeneous 
populations, we propose the design of a multistage microfluidic platform which consists of 
a microfluidic sorter upstream of a convective mechanical transfection stage as future 
work. The sorter will be used to split heterogeneous iPSC populations into subpopulations 
much more homogenous in size. These subpopulations will then be transfected using 
transfection channels optimized for each subpopulation, enabling high-efficiency delivery 
of large macromolecules to iPSCs. 
1.3.2 Significance 
In this aim, we demonstrated the first ever convective microfluidic delivery of CRISPR 
genome-editing reagents to patient-derived iPSCs. Further, we performed the first ever 
extensive characterization of the size of iPSCs in suspension, which resulted in the 
discovery of significant size heterogeneity in patient derived iPSCs. This discovery 
suggests that multistage microfluidic devices which sort cell by size before transfection 
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could dramatically increase the efficiency of microfluidic delivery of large constructs to 
patient-derived iPSCs.  
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CHAPTER 2. MICROFLUIDIC PROCESSING OF STEM CELLS 
FOR AUTOLOGOUS CELL REPLACEMENT 
2.1 Abstract 
Autologous photoreceptor cell replacement is one of the most promising approaches 
currently under development for the treatment of inherited retinal degenerative blindness. 
Unlike endogenous stem cell populations, induced pluripotent stem cells (iPSCs) can be 
differentiated into both rod and cone photoreceptors in high numbers, making them ideal 
for this application. That said, in addition to photoreceptor cells, state of the art retinal 
differentiation protocols give rise to all of the different cell types of the normal retina, the 
majority of which are not required and may in fact hinder successful photoreceptor cell 
replacement. As such, following differentiation photoreceptor cell enrichment will likely 
be required. In addition, to prevent the newly generated photoreceptor cells from suffering 
the same fate as the patient’s original cells, correction of the patient’s disease-causing 
genetic mutations will be necessary. In this review we discuss literature pertaining to the 
use of different cell sorting and transfection approaches with a focus on the development 
and use of novel next generation microfluidic devices. We will discuss how gold standard 
strategies have been used, the advantages and disadvantages of each, and how novel 
microfluidic platforms can be incorporated into the clinical manufacturing pipeline to 
reduce the complexity, cost and regulatory burden associated with clinical grade 




Development of patient-derived induced pluripotent stem cells, next-generation 
sequencing and genome editing technologies have fueled the field of personalized 
medicine, which can be defined broadly as use of the patient’s own data to inform diagnosis 
and develop customized treatments. Autologous cell replacement is at the leading edge of 
this field. The most promising autologous cell replacement strategies currently under 
development rely on the use of induced pluripotent stem cells (iPSCs), which require 
tissue-specific differentiation prior to transplantation. For instance, we and others have 
shown that following subretinal transplantation, iPSC-derived photoreceptor precursors 
cells are able to restore retinal function in animal models of retinal degenerative blindness 
[3]–[12]. Following decades of development, the vast majority of the differentiation 
protocols reported faithfully recapitulate normal retinal development, which means that 
they give rise to each of the different cell types found in the retina [12]–[42]. For 
therapeutic photoreceptor cell replacement, enrichment of photoreceptor precursor cells 
away from the unwanted cell types (i.e., retinal ganglion cells, bipolar inter neurons, retinal 
pigmented epithelial (RPE) cells, etc.) will be desirable. 
In addition to requiring the use of sorting technologies, autologous stem cell therapies for 
inherited diseases are also likely to require a method for delivering reagents to the interior 
of cells in order to modify their genome prior to differentiation and transplantation. For 
instance, when using patient-derived induced pluripotent stem cells to generate 
photoreceptors for the treatment of inherited retinal degenerative blindness, the disease-
causing genetic defect that initially resulted in photoreceptor cell dysfunction and death 
will likely need to be repaired prior to transplantation. As we and others have shown, repair 
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can be accomplished by delivering macromolecules such as Cas9 and homology dependent 
repair (HDR) sequences to patient derived iPSCs followed by clonal selection and cell line 
expansion [43]–[45]. 
In this review, we will discuss common techniques for both cell sorting and transfection 
and show how current ‘gold standard’ methods compare with new state of the art 
microfluidic approaches for stem cell processing. In doing so we will discuss how novel 
microfluidic strategies have the potential to decrease the cost, complexity and regulatory 
burden associated with conventional approaches. 
2.3 Cell Sorting Techniques 
2.3.1 Label Based Strategies 
Currently, fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting 
(MACS) constitute the gold standard of cell sorting approaches. Both techniques are 
selective and capable of processing cells with very high throughput. Selectivity is most 
commonly conferred via the use of antibodies designed to target specific cell surface 
antigens. 
  For FACS, cells are first labeled using fluorescent antibodies, dyes or genetic 
reporters. They are then passed one cell at a time through a series of lasers, which each 
excite the cell at a specific wavelength. The light emitted by these fluorophores is then 
detected by photodetectors, which allow for the identification of the fluorescent signal 
present. Based on the markers detected, a FACS machine can then deposit different cell 
populations into separate containers using electrostatic force to deflect single cell liquid 
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droplets. This approach has been used widely for mouse photoreceptor cell isolation and 
subsequent subretinal transplantation. For instance, several groups have used reporter 
mouse strains engineered to express green fluorescent protein under control of the NRL 
promoter to isolate photoreceptor precursor cells at various stages of retinal development 
to evaluate the role of cellular maturation on functional integration following 
transplantation [46]–[48]. Similarly, using genetically modified pluripotent stem cell 
fluorescent reporter lines, several groups have adopted this sorting strategy for evaluating 
human retinal development in vitro and to identify photoreceptor precursor cells following 
isolation and subretinal transplantation in vivo [49]–[51]. Unfortunately, this strategy relies 
on endogenous expression of a cell type-specific fluorophore and as such is unlikely to be 
useful for clinical application. This is especially true for photoreceptor cell replacement 
where endogenous expression of a fluorescent protein such as GFP would likely interfere 
with normal visual function. 
Unlike FACS, MACS relies exclusively on the use of antibodies to attach paramagnetic 
beads to the surface of cells, which allows these cells to be pulled out of suspension using 
a strong magnet. Once isolated, antibody bound beads can be released and cells used for 
downstream applications. For instance, several groups have used cluster of differentiation 
antigen 73 (CD73) antibody-bound magnetic beads to isolate photoreceptor precursor cells 
that retain the ability to integrate into the rodent retina following transplantation [52]–[56]. 
Like many cell surface markers, CD73 has been reported to be expressed on a variety of 
different cell types [57]–[59]. For enhanced specificity, Lakowski and colleagues 
demonstrated that a panel of 5 cluster of differentiation antigens (i.e., CD73+, CD24+, 
CD133+, Cd47+ and CD15-) could be used to isolate photoreceptor precursor cells from 
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embryonic stem cells [57]. Unfortunately, the MACS approach is not well suited for 
multiple marker-mediated isolation of specific cell populations as selecting for multiple 
markers would require sequential isolation, increasing the difficulty of the procedure while 
also increasing cell loss. As such, the above-described study was performed using FACS.  
Interestingly, as shown in Figure 2, in both developing fetal and adult human retina CD73 
appears to be predominantly expressed on a subset of Rod photoreceptor cells. While the 
lack of expression in non-photoreceptor cell types in the human retina is desirable, the fact 
that CD73 does not appear to be expressed by cone photoreceptor cells, even during early 
retinal development, is of concern for cell replacement, as cone photoreceptor cells will be 
required to restore high acuity vision. Interestingly, Gagliardi and colleagues convincingly 
demonstrate that human CD73 enriched photoreceptor precursors have the ability to give 
rise to cells expressing blue and red/green cone opsin following subretinal transplantation 
[52]. As such, additional lineage tracing studies to demonstrate the fate of CD73-positive 
progenitor cells are needed if this approach is to be used clinically. 
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Figure 2. CD73 expression in the adult and developing fetal human retina. A-C: 
Single-cell RNA sequencing of adult human retinal cells [60] demonstrates that the NT5E 
gene that encodes CD73 is expressed by a select population of mature rod photoreceptor 
cells only. D-F: Re-processed single-cell RNA sequencing of developing fetal human 
retinal cells [61] demonstrates that NT5E is predominantly expressed by committed rod 
photoreceptor cells, with very infrequent expression in retinal progenitor cells and 
developing cone photoreceptor cells. 
While MACS and FACS can be useful for cell sorting, as indicated above, to be clinically 
relevant, cell surface antigens and corresponding antibodies are required. Unfortunately, in 
many cases targetable antigens either do not exist or are not expressed solely on the cell 
type of interest, making these approaches challenging to apply successfully. For instance, 
until recently cell surface antigens useful for isolation of corneal limbal stem cells remained 
elusive. Although we were able to demonstrate that ABCB5 was expressed on limbal stem 
cells and could be used for cellular enrichment to successfully treat animal models of 
limbal stem cell deficiencies, this marker is not Limbal stem cell specific [62]–[64]. 
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Similarly, markers that are often used for stem cell-derived vascular endothelial cell 
enrichment (e.g., CD31) are expressed on a variety of different endothelial cell populations 
and monocytic cells, making them less than ideal for isolation of tissue specific vascular 
subtypes [65]–[67].  
2.3.2 Label Free Strategies 
In regenerative medicine, therapeutic stem cells or their progeny are typically transplanted 
into patients to rebuild injured tissues. For clinical cell replacement, all reagents applied to 
the cells must be fully characterized and guaranteed to be safe in order to gain regulatory 
approval. The use of fluorescent and/or magnetic bead bound antibodies that target specific 
cell surface antigens for cell sorting, increases the labor and regulatory burden associated 
with clinical translation. For instance, conjugation of antibodies to cells destined for 
transplant followed by sorting is both time consuming and has the potential to alter cell 
function and compromise both safety and the effectiveness of the treatment. In addition, 
FACS, which requires a complex specialized piece of equipment, presents significant 
manufacturing challenges. For autologous cell replacement for instance, FACS protocols 
must reliably prevent cross contamination of patient derived cell lines following sequential 
sorting. This would likely require a complete sterilization between each sorting run. Sorting 
strategies that utilize pre-sterilized single use devices that do not require specialized 
reagents would be much more desirable. To address concerns associated with label-based 
cell enrichment, a variety of different label-free microfluidic cell sorting approaches are 
being developed. Microfluidic sorting methods are typically designed to sort cells based 
on physical characteristics such as diameter and stiffness, which avoids reliance on the 
presence of unique cell surface antigens and reagents. These platforms are generally 
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implemented as cheap, disposable chips driven by an external pump (e.g., syringe pump or 
peristaltic pump). Such label free approaches are ideal for isolation of cells with unreliable 
or absent cell surface antigens and terminally differentiated stem cell progeny that are 
destined for clinical cell replacement. Two of the most commonly used microfluidic device 
designs published to date are 1) deterministic lateral displacement (DLD) and 2) 
hydrodynamic focusing. There are also many label free cytometry approaches being 
developed, such as ghost cytometry [68], impedance cytometry [69] and deformability 
cytometry [70] which will likely play an important role in cellular analysis going forward. 
However, these platforms have not yet been integrated into cell sorters, so we will not be 
covering them in depth in this review. 
2.3.2.1 Deterministic Lateral Displacement 
As shown in Figure 3A, in deterministic lateral displacement (DLD) a series of microposts 
are used to move cells perpendicular to the direction of fluid flow in a manner related to 
their size and stiffness. Several groups have successfully used this approach to separate a 
variety of different cell types [71]–[73]. For instance, Xavier and colleagues recently 
demonstrated how this approach could be used to isolate skeletal progenitor cells from 
human bone marrow [71].  Specifically, they showed that by using DLD they could 
successfully isolate skeletal progenitor cells, which were stiffer than leukocytes and 
contained within the larger cell fraction of bone marrow. These isolated progenitor cells 
retained their ability to form clones in cultures indicating that they retained their stem cell 
potential. One of the drawbacks of DLD however, is that it is susceptible to clogging. As 
cell debris and/or aggregates cannot easily escape the active region of the DLD device they 
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become trapped, disrupting the flow pattern required for sorting, which in turn negatively 
impacts enrichment efficiency.  
 
Figure 3. Next-generation microfluidic cell sorting strategies. A-C: Microfluidic cell 
sorting strategies that utilize deterministic lateral displacement (A, adapted from [74], 
streamlines obtained via CFD simulation), hydrodynamic focusing (B, Adapted from [75]) 
and cellular compression with lateral deflection (C). For DLD, cells start in a given 
streamline. If the cell is larger than a critical size, it is displaced laterally into a new 
streamline due to interaction with the posts (P). For hydrodynamic focusing, the balance 
between a wall interaction force, a shear gradient lift force and Stokes drag dictates the 
presence of equilibrium positions for cells suspended in a liquid. Over time, cells will tend 
to occupy equilibrium positions within the channel, resulting in size-based focusing. For 
cellular compression with lateral deflection, the sorting platform consists of a series of 
diagonal constrictions designed to deflect cells laterally relative to the main direction of 
flow in a manner related to their size and mechanical properties. 
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2.3.2.2 Hydrodynamic Focusing 
Hydrodynamic focusing uses hydrodynamic forces to cause cells to come to an equilibrium 
position a channel. As illustrated in Figure 3B, this equilibrium position is determined by 
balancing of lift and drag forces, which is a function of cell size and biomechanical 
properties (i.e., stiffness and viscosity). Like DLD, hydrodynamic focusing has been used 
successfully to sort a variety of different cell types, including endogenous stem cells [76]–
[78]. For instance, Hur and colleagues were able show how hydrodynamic focusing could 
be used to isolate adrenal cortical progenitor cells from a mixed cell population obtained 
from digestions of murine adrenal glands [76].  Separation was accomplished by exploiting 
the differing strengths of cell-cell adhesion between undifferentiated precursors and 
differentiated somatic cells. Given that the cell-cell junctions are stronger between 
differentiated cells than undifferentiated cells, a digestion protocol was developed which 
resulted in complete dissociation of progenitor cells leaving the differentiated somatic cells 
in larger clumps. The clumps and single cells could then be hydrodynamically sorted by 
size to effectively separate progenitor cells from the contaminating somatic cells with little 
to no reduction in viability (i.e., not significantly different from unsorted control samples). 
As enriched adrenal progenitor cells could subsequently be expanded in culture, it is 
conceivable that these cells could be given back to the patient from whom they were 
derived in order to restore adrenal function. One drawback of this technique is that it takes 
relatively large differences in cell size and/or stiffness to result in detectable differences in 
equilibrium position.  
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2.3.2.3 Our Platform 
Due to the issues mentioned above, neither DLD nor hydrodynamic focusing are ideal for 
sorting of pluripotent stem cell derived photoreceptor precursor cells from each of the 
different cell types derived following retinal differentiation [16], [23]–[33], [79]–[84]. 
Specifically, following retinal organoid dissociation clusters of RPE and/or inner retinal 
cell types is common, as such the potential for DLD device clogging is high.  Similarly, 
the differences in size between retinal cells that are liberated from organoids are less than 
ideal for efficient hydrodynamic sorting. To address these concerns, we recently developed 
the microfluidic cell sorting platform illustrated in Figure 3C. Using this device cells are 
exposed to repeated compressions by a series of thin ridge constrictions oriented diagonally 
to the direction of flow. In our hands, these repeated compressions do not have a significant 
impact on cell viability [85]. As cells interact with these constrictions, which are designed 
to be smaller than the cell’s diameter, they deflect laterally in the device in a manner related 
to their size and stiffness. The performance of this platform is dependent on the gap size 
and as such must be reoptimized for each application. The design of the constrictions 
allows cell debris and aggregates to move along the constrictions into a gutter and exit the 
device without causing clogs. At the end of the device there are 5 independent wells from 
which sorted cell populations can be collected. To evaluate the utility of this platform, we 
recently performed a series of experiments using iPSC derived photoreceptor precursor and 
RPE cell lines as well as human donor retina [86]. When photoreceptor precursor and RPE 
cells were mixed at a ratio of 37% RPE to 63% photoreceptor precursor cell and injected 
into the device at a concentration of 2x106 cells per mL, we were able to reliably separate 
the photoreceptor precursor cells from the RPE cells. Similarly, when human donor retina 
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was dissociated and sorted using the device, we were able to isolate independent samples 
enriched for RPE (largest fraction in well 1), rod and cone photoreceptor cells (largest 
fraction in well 4) and inner retinal neurons, including retinal ganglion cells (enriched in 
wells 1-3) [86]. Although we believe that there is still room for further improvement, these 
findings demonstrate that retinal cells can be separated into discrete populations by 
exploiting differences in cell size, stiffness and viscosity [87]–[89] (i.e., without the need 
for antigen specific antibodies or fluorescent markers). Moreover, naturally occurring stem 
cells may be processed in a similar manner to enrich for desired cell phenotypes [90]. 
2.4 Transfection Techniques  
Since autologous iPSCs possess the same genome as the patient from whom they are 
derived, the use of these cells for treatment of inherited disease will likely require 
correction of the disease-causing genetic variants that resulted in death of the target cell 
type prior to differentiation. Genome editing approaches that utilize zinc finger nucleases, 
Talens or CRISPR/Cas9 to induce double strand DNA breaks and homology directed repair 
of target genetic loci, have been used for this purpose [91]–[93]. In addition, next-
generation CRISPR technologies including base editors, primer editors and RNA-targeting 
Cas effectors, which can be used to restore gene function in the absence of double strand 
DNA break induction, are promising new approaches [94]. For these strategies to work, 
delivery of nucleic acid and/or protein to patient derived iPSCs, followed by genetic 
screening and expansion of genetically corrected clones, is required. Although several 
strategies for delivering genome editing reagents to iPSCs exist, the most widely used are 
1) viral transduction, 2) chemical transfection and 3) electroporation.  
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2.4.1 Viral Transduction 
Viral transduction takes advantage of the native ability of viruses to insert their DNA into 
infected cells. By replacing the genetic material required for replication, viruses can be 
engineered to deliver sequences of interest to a variety of different cell types with high 
efficiency. For instance, adeno associated viruses (AAV) are used extensively in both pre-
clinical and clinical settings to safely deliver therapeutic DNA to photoreceptor cells and 
mitigate disease progression [95]–[99]. Unfortunately, the packaging capacity of AAVs is 
limited to approximately 4.7kb, making them less useful for delivery of the genome editing 
reagents required to induce homology directed repair in patient derived iPSCs in vitro since 
CRISPR/Cas9 and repair templates exceed this limit. For this reason, lentiviruses, which 
have a payload of approximately 8kb, have been widely used for genome editing of patient 
derived iPSCs [100]–[103]. Although successful, the major drawback associated with the 
use of lentivirus is that they carry increased risk of inducing insertional mutagenesis 
resulting from random insertion of the genetic payload into the host cell’s genome [104]. 
In addition, viruses are only useful for delivery of nucleic acids, which precludes their use 
for CRISPR mediated genome editing via delivery of ribonuclear proteins, which are often 
significantly more efficient [105], [106].  
2.4.2 Chemical Transduction Techniques 
Chemical reagents such as lipofectamine are quite common for delivery of macromolecules 
given that they are not subject to the packaging size limitation that viruses are subject to. 
These techniques involve conjugating a positively charged carrier with target nucleic acids. 
This positively charged complex is then attracted to the cell membrane, whereby it is taken 
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up via endocytosis. One of the greatest advantages of this approach is the ease and speed 
with which it can be utilized. Specifically, unlike viral transduction, which requires 
engineering of a viral plasmid and packaging into viral particles by trained technical staff 
using well characterized safety protocols, lipofection can be safely performed using almost 
any expression plasmid.  
2.4.3 Electroporation 
As with lipofection, electroporation also avoids concerns associated with cargo size limits. 
Electroporation works via exposure of cells to large electric fields that cause pores to form 
transiently in the cell membrane through which macromolecules can enter. Both lipofection 
and electroporation have been used extensively by us and others for CRISPR mediated 
correction of patient derived iPSCs with excellent success [91], [107]. The major drawback 
of both techniques is that they use proprietary reagents that would be subject to FDA 
regulation when used for clinical cell replacement. As these reagents are not typically 
produced under and compliant with cGMP the regulatory burden associated with their use 
is high.  
2.4.4 Microfluidic Transfection 
To address these concerns, we and others have pioneered the use of novel microfluidic 
approaches designed to deliver macromolecules to cells without the need for specialized 
reagents. In general, microfluidic transfection strategies rely on physical deformation of a 
cell to induce pore formation. Macromolecules (nucleic acids, proteins, etc.) are then 
delivered by either diffusion or convective transport. These transfections are generally very 
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fast (less than an hour of processing time) after which the cells can be re-plated and 
expanded for downstream selection, clonal expansion and validation. 
2.4.4.1 Microfluidic Transfection Mediated By Diffusive Transport 
In 2008, Hallow and colleagues demonstrated that fluid shear forces can be used to deliver 
a macromolecule cargo into cell lines [108]. In 2012 Sharei and colleagues reported the 
development of a microfluidic cellular transfection device that was designed to deliver 
macromolecules to cells by passing them through a narrow constriction at high flow rates 
[109]. By squeezing the cells into a small channel, the authors demonstrated that they could 
cause pores to form in the cell membrane through which a payload suspended in the 
surrounding buffer could be passed into the cell through diffusive transport (Figure 4A). 
By using mechanical forces to induce pore formation, this approach removes the need for 
proprietary reagents necessary for common transfection strategies such as lipofection and 
electroporation. In addition, devices are relatively simple, which allows for mass 
production and distribution as single use disposable units eliminating the need for complex 
pieces of equipment and worry about cross contamination of independent patient samples. 
Collectively these advantages are significant when trying to deploy the technology under 
current Good Manufacturing Practice (cGMP) for autologous clinical cell replacement. 
This approach, however, is not without its drawbacks. Most importantly, given that the 
payload enters the cell through passive, diffusive transport, delivery efficiency when using 
this technique is inversely related to payload size. For instance, when delivering fluorescent 
dextran molecules of varying size to murine embryonic stem cells, Sharei et al. 
demonstrated a drop in delivery efficiency from approximately 50% for 3kDa dextran to 
approximately 25% when 70kDa dextran was used [109].  
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Figure 4. Next-generation microfluidic cell devices. A-B: Schematics depicting 
diffusive (A) and convective (B) microfluidic cell transfection device designs. Red 
arrowheads denote net direction of macromolecular transport across the cell membrane. 
Black arrow denotes direction of fluid flow. C: Schematic and preliminary data 
demonstrating microfluidic delivery of a large multicistronic construct containing sgRNAs, 
Cas9, GFP reporter and associated promoters to patient-derived iPSCs. Delivery of the 
same construct using Lipofectamine Stem, which we have previously used for CRISPR 
correction of patient iPSCs [93], has been included for comparison. 
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2.4.4.2 Microfluidic Transfection Mediated By Convective Transport 
To address issues associated with reduced delivery efficiencies with increased cargo size, 
our group recently developed another microfluidic delivery platform, which subjects cells 
to repeated, rapid compressions [85]. During these rapid compressions, the volume of the 
compressed cell decreases, followed by partial volume recovery between compressions 
(Figure 4B). As shown in Figure 4C, in preliminary experiments we have been able to 
deliver a large multicistronic CRISPR construct containing gene-specific sgRNA 
sequences, Cas9 and a GFP report construct with associated promoters, to human patient 
derived iPSCs at an efficiency similar to that obtained using Lipofectamine Stem. As 
CRISPR mediated genomic correction of iPSCs is typically achieved by transient 
transfection followed by clonal selection and expansion [110], [111], high transfection 
efficiency is not a requirement for genomic correction. That said, unlike the above-
described approach, the volume changes created using this device cause active, convective 
transport of the payload suspended in the surround buffer across the cell membrane. The 
most important consequence of this convective delivery mechanism is that delivery 
efficiency is not a strong function of payload size. For instance, a relatively constant 
delivery efficiency of greater than 80% was demonstrated for delivery of dextrans that were 
4kDa and 2000 kDa in size to K562 myelogenous leukemia cells. With some optimization 
(see future perspectives section below) we believe that efficient transfection of patient 
derived iPSCs will be possible. As with the diffusive transfection approach described 
above, use of this convective transfection strategy does not require specialized reagents or 
proprietary materials. Likewise, devices can be readily fabricated and provided as sterilized 
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single use devices, which is ideal for manufacturing of autologous cell replacement 
products. 
In addition to cGMP compatibility, both the techniques described above are amenable to 
massive parallelization. Due to the small size of each individual channel, many channels 
can be fabricated on a single chip with shared inputs and outputs, drastically increasing 
throughput without increasing device cost or the usability of the platform. 
2.5 Future Perspectives 
While the microfluidic techniques presented in this paper have the potential to enable the 
manufacture of safe, high potency cell therapies, there are some shortfalls, which the 
community is continuing to address. First, while label-free microfluidic sorting strategies 
have advantages over ‘gold standard’ techniques in terms of cost and safety, they are still 
not as selective as FACS or MACS. While we expect the performance of these new devices 
to continue to improve, it may be that microfluidic cell sorting will never perform as well 
as antibody-based methods, provided that appropriate markers exist. It is the belief of the 
authors that emerging label-free microfluidic sorting techniques can complement ‘gold-
standard’ techniques by serving as an alternative when either, 1) appropriate targets for 
antibody labels do not exist, 2) the conjugation of antibodies to cells pre-sort could interfere 
with the cell’s utility in downstream applications, 3) sterilizing multi-use instrumentation 
becomes burdensome or 4) the cost of purchasing/operating large commercial sorters 
becomes prohibitive.  
As discussed above, the performance of microfluidic transfection technologies is highly 
dependent on proper selection of device geometry to ensure sufficient deformation of cells 
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to facilitate transfection without destroying the cells or clogging the device. While this 
optimization is more straightforward with a relatively homogeneous cell population, things 
rapidly become complicated when attempting to transfect heterogeneous samples. One can 
imagine that for a fixed device geometry, cells of differing size in a mixed population will 
respond differently. The smallest cells in the population may not be adequately deformed 
to allow for transfection, while the largest cells may be damaged due to excessive 
deformation or simply clog the device, resulting in loss of valuable cell product and time. 
It is possible that this issue can be addressed by ‘pre-sorting’ a heterogeneous cell 
population into more homogeneous fractions, and then transfecting each fraction 
containing useful cells using separate devices. 
In addition to the technical limitations of emerging technologies, there is also the issue that 
new microfluidic sorting and transfection platforms currently do not exist as ‘out of the 
box’ solutions. This is especially problematic when attempting to implement the 
technology into an existing clinical production pipeline. Unlike existing technologies such 
as FACS that have been in widespread use and are familiar to the FDA, implementation of 
novel microfluidic devices will likely require extensive validation and pose a significant 
regulatory burden. Generally, device geometries and process parameters need to be re-
tuned for new applications, and this optimization generally must be done by someone 
familiar with the platform of interest. While these issues will likely become less 
pronounced as the technologies mature, we believe that increased communication and 
collaboration between the stem cell and microfluidics communities is essential in ensuring 
that these new microfluidic platforms are developed and distributed in a way that is most 
 28 
beneficial to the research needs of the stem cell community and most translatable to the 
treatment of patients. 
2.6 Summary 
Autologous photoreceptor cell replacement for the treatment of inherited retinal 
degenerative blindness is at the forefront of personalized medicine. Unfortunately, 
complexities associated with this approach present significant manufacturing challenges. 
In general, biologics manufacturing is designed for mass production of a single product to 
treat a large number of individuals (e.g., vaccine production). Autologous photoreceptor 
cell replacement requires that a unique line of iPSCs be generated, genetically corrected, 
and differentiated for every patient in need, in order to prevent immune rejection. 
Following differentiation, photoreceptor precursor cells must be isolated and delivered 
independent of the other retinal cell types that are generated during the differentiation 
process. Although many of the reagents required for manufacturing of autologous iPSC-
photoreceptor cells are cGMP compliant, gold standard approaches used for genetic 
correction of patient derived iPSCs and sorting of photoreceptor precursor cells following 
differentiation require reagents and equipment that are not well suited to clinical 
manufacturing. As described in this review, novel microfluidic strategies are being 
developed for both cellular enrichment and transfection that do not require specialized 
reagents and complex equipment. By incorporating these microfluidic strategies into 
autologous photoreceptor cell manufacturing pipelines we believe that it will be possible 
to greatly reduce the cost, protocol complexity and regulatory burden associated with 
production of autologous photoreceptor cells for treatment of retinal degenerative 
blindness. 
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CHAPTER 3. LABEL-FREE MICROFLUIDIC ENRICHMENT 
OF CANCER CELLS FROM NON-CANCER CELLS IN ASCITES 
3.1 Abstract 
The isolation of a patient's metastatic cancer cells is the first, enabling step toward 
treatment of that patient using modern personalized medicine techniques. Whereas 
traditional standard-of-care approaches select treatments for cancer patients based on the 
histological classification of cancerous tissue at the time of diagnosis, personalized 
medicine techniques leverage molecular and functional analysis of a patient's own cancer 
cells to select treatments with the highest likelihood of being effective. Unfortunately, the 
pure populations of cancer cells required for these analyses can be difficult to acquire, 
given that metastatic cancer cells typically reside in fluid containing many different cell 
populations. Detection and analyses of cancer cells therefore require separation from these 
contaminating cells. Conventional cell sorting approaches such as Fluorescence Activated 
Cell Sorting (FACS) or Magnetic Activated Cell Sorting (MACS) rely on the presence of 
distinct surface markers on cells of interest which may not be known nor exist for cancer 
applications. In this work, we present a microfluidic platform capable of label-free 
enrichment of tumor cells from the ascites fluid of ovarian cancer patients. This approach 
sorts cells based on differences in biomechanical properties, and therefore does not require 
any labeling or other pre-sort interference with the cells. The method is also useful in the 
cases when specific surface markers do not exist for cells of interest. In model ovarian 
cancer cell lines, the method was used to separate invasive subtypes from less invasive 
subtypes with an enrichment of ~6-fold. In ascites specimens from ovarian cancer patients, 
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we found the enrichment protocol resulted in an improved purity of P53 mutant cells 
indicative of the presence of ovarian cancer cells. We believe that this technology could 
enable the application of personalized medicine based on analysis of liquid biopsy patient 
specimens, such as ascites from ovarian cancer patients, for quick evaluation of metastatic 
disease progression and determination of patient-specific treatment. 
3.2 Introduction 
Metastasis is the primary cause of cancer-related death. The American Cancer Society has 
predicted 21,750 new diagnoses of ovarian cancer and 13,940 deaths due to ovarian cancer 
in 2020 [112]. Metastasis plays a large role in ovarian cancer related mortality, given that 
75% of ovarian cancer patients already have metastatic disease at the time of diagnosis, 
resulting in a five year survival rate of only 48.6% [112], [113]. 
Detecting and analyzing metastasizing cancer cells in locations of the body in which the 
cancer cells are a minority population remains a challenge. A consequence of the inability 
to identify and isolate rare metastatic cells for molecular characterization and drug testing 
is the inability to optimize chemotherapies; this contributes to the lack of progress in 
addressing metastatic cancers. A variety of techniques have been developed to enrich 
cancer cells, usually requiring conjugation of antibodies to surface antigens, which may 
not be specific to the cells of interest. For example, a magnetic bead capture and isolation 
immunoassay [114], [115], while sensitive to ovarian cancer cells, is expensive to 
implement and requires the use of antibodies against specific surface markers that may not 
be present on cancer cells or may also exist on healthy cells. Similar limitations exist with 
fluorescence activated cell sorting (FACS). While an adherence assay has been developed 
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to enrich ovarian cancer cells [116], which does not rely on the use of antibody conjugation 
and sorting, this method requires 2-3 days for cells to be adhered, washed, and cultured.  
To improve the accuracy of downstream analyses of metastatic cells, there is a need for 
label-free and high-throughput methods for enriching cancer cells within fluids, which 
includes effusions, ascites, lymph, and blood. The benefits of obtaining more highly 
purified cancer cell samples include increased sensitivity to gene expression diagnostics. 
Higher purity samples will then result in accelerated cancer biology research and improved 
treatments by clinicians through more accurate and sensitive outcomes of analytical 
techniques. Enriching cancer cells will also enable molecular readout methods, for example 
ELISA, PCR, and FISH, to enhance scientific discovery, such as determining whether 
prognostic markers of primary tumors differ from cells in effusions [117]. Ovarian cancer 
is a particularly important pathology for enrichment techniques, considering the general 
poor quality of existing biomarkers [118]–[120]. For example, one marker used to assess 
malignancy in ovarian cancer is TGM2, but unfortunately the resulting protein TG2 is 
expressed in a wide variety of tissues and detectible in all organs [121]. 
Detection of circulating tumor cells can rely on differences in tumor cell biomechanical 
properties, especially cell size. Moreover, other cell biomechanical properties have shown 
use as biomarkers for enriching cancer cells from non-cancer cells. Using several different 
experimental techniques, abnormalities in the biophysical properties of tumor cells have 
been widely studied in primary and cultured cells [122]–[124] with specific examples 
including prostate cancer [125], bladder cancer [126], breast cancer [127]–[129], 
esophageal cancer [130], thyroid cancer [131], oral cancer [132], ovarian cancer [133], 
pancreatic cancer [134], and leukemia [135], [136]. The molecular mechanisms for the 
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change in cell stiffness are likely a result of remodeling of cytoskeletal pathways [137] and 
nuclear composition [138]. The mechanical properties of exfoliated cancer cells have been 
shown to undergo drastic alterations compared to and distinct from healthy counterparts. 
Cross et al. have  quantified breast cancer cell stiffness, by a parameter called Young’s 
modulus, and showed a correlation of stiffness with cell malignancy [139]. In their work, 
the stiffness of metastatic cancer cells taken from the pleural fluids of patients with breast 
cancer is more than 70% softer, with a standard deviation over five times narrower, than 
benign reactive mesothelial cells. Similar results were obtained using different 
methodologies by Guck et al. in breast epithelial cells [127]. These results suggest 
biomechanical analysis can distinguish cancerous cells from noncancerous cells, even if 
their morphologies are similar [140]. In prior work studying the mechanical properties of 
ovarian cancer cell lines, we have used atomic force microscopy (AFM) to show that more 
invasive ovarian cancer cells are softer than less invasive cells [137] and nonmalignant 
epithelial cells, indicating that cell stiffness may be a useful biomarker for use in diagnosis 
of ovarian cancer and isolation of metastatic cells.  
While several microfluidic approaches have been described for the high frequency 
measurement of cell stiffness [127], [135], [141], the number of methods available for 
sorting of mechanically distinct cell types is fairly restricted. Several approaches have been 
developed to sort cells based on size [142], [143]. Two approaches for sorting cells by size 
include hydrodynamic focusing and ferrohydrodynamic cell separation. In hydrodynamic 
focusing, cells are pumped at high speed down microfluidic channels. A balance of forces 
due to drag and wall induced lift then dictate that cells occupy equilibrium positions in the 
channel which are a function of their size and biomechanical properties. This approach, 
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while high throughput and simple, suffers from low sensitivity given that changes in cell 
size only cause a moderate change in equilibrium position. Another size-based sorting 
method is ferrohydrodynamic cell separation. When using this approach, cells are 
immersed in a ferrofluid and pumped through a channel which is placed in a magnetic field. 
The interactions of this ferrofluid with the magnetic field induce a buoyancy force on the 
cells proportional to their volume. Stiffness-based sorting methods primarily rely on one 
of two approaches: 1) confined geometries (i.e. pillars), which slow the flow of stiff cells 
[144] or 2) inertial focusing, which cause stiff cells to translate laterally in the channel with 
respect to soft cells due to nonlinear effects in channel flow [76], [145]. A limitation of the 
pillar approach is that samples are processed relatively slowly with low throughput. A 
limitation of the inertial focusing approach is that the sensitivity to cell stiffness is small, 
as soft and stiff cells displace only a fraction of a cell diameter. The limited sensitivity 
requires more precise flow control, making it difficult to obtain multiple, biophysically 
distinct outputs and improved fractionation of heterogeneous cells. To address the need for 
a high-throughput label-free enrichment strategy for malignant ovarian cancer cells, we 
demonstrate the optimization and use of a microfluidic device for the isolation of malignant 
cells from primary ascites samples. The device design is similar to those used previously 
to isolate retinal cells and stem cells [146], [147]. The microfluidic device itself is 
biologically inert and sorts cells based on their mechanical and physical properties into 
biologically meaningful fractions. These fractions can be tailored based upon modification 
of the device parameters and flow conditions. To facilitate the optimization of this platform 
for different sorting applications we have developed a computational model that couples 
the resistance to cell deformation, determined from cell size and measured Young’s 
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modulus, as well as hydrodynamical forces of the flow (3D flow trajectories) to model the 
trajectories of the cell under the ridge. The results are described in more detail in [148]. 
3.3 Methods 
3.3.1 Device Design and Fabrication 
The microfluidic sorting devices were fabricated using standard photolithography and 
replica molding process. Silicon masters fabricated using photolithography were prepared 
to mold a polydimethylsiloxane (PDMS) chip replicating the microchannel design. The 
PDMS chip was prepared with inlet and outlet holes formed with a biopsy punch and 
bonded onto a glass slide using oxygen-plasma bonding (Harrick Plasma, USA). The 
fabricated devices were passivated using 1% BSA solution by incubating for one hour at 
37°C to reduce the non-specific adhesion of cells with the channel surface. The number of 
ridges and the angle was chosen to be 14 and 30° respectively, based upon an optimization 
of hydrodynamic and elastic forces [148]. The gap size was chosen to be 9 μm to provide 
sufficient compression for sorting while not causing excessive cell deflection in stiffer 
populations. 
3.3.2 Cell line preparation and sorting 
Ovarian cancer cell lines were used to optimize the microfluidics processing. OVCAR-3 
and HEY-A8 were originally provided by Dr. G. Mills (MD Anderson Cancer Center, 
Houston, TX) and cultured in the laboratory using RPMI-1640 media with 10% FBS and 
1% penicillin-streptomyocin. Once the cells were 70% confluent, they were washed with 
phosphate buffered saline (PBS) (without calcium and magnesium) and dyed using 
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following procedure. OVCAR-3 and HEY-A8 cells were dyed with Cell Tracker Deep Red 
and Cell Tracker Green CMFDA respectively as per the protocol provided by the 
manufacturer (ThermoFisher). Then, the cells were trypsinized and mixed with the flow 
buffer (35% Percoll, 1% BSA, 1% EDTA and 0.006% Tween in PBS[-,-]) at a 
concentration of approximately 5 x 106 cells/mL and infused into the device at a flow rate 
determined to result in the best separation of cell samples. Each device inlet was connected 
to a syringe pump (PHD-2000, Harvard Apparatus) using plastic tubing, Luer lock adapters 
and blunt Luer lock needles. The cell sample was then infused at a flow rate of 15 μL/min. 
Flow buffer was infused into the left and the right sheath inlets at 25 and 10 μL/min 
respectively to position the cell flow stream optimally off-center in the channel. The sorted 
cells were collected at the outlets using pipette tips and counted using flow cytometry.  
3.3.3 Trajectory Analysis 
The trajectories of the ovarian cancer cell types were recorded using high-speed optical 
microscopy (Vision Research Phantom v9.0). Videos from each cell type were analyzed 
using ImageJ to identify where individual cells came into contact with each ridge. Video 
pixels were converted to microns and video tilt between the primary flow direction and 
video orientation were corrected using a custom R program. This program 
(https://github.com/nstone8/Manual-Tracking) was used to convert the locations at which 
the cell impacted each ridge into cumulative deflection per ridge data to characterize 
trajectory of each cell type. 
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3.3.4 Ascites Sorting for NGS Sequencing 
Primary ascites specimens were obtained from two patients from Northside Hospital 
(Atlanta, Georgia) (Figure 1.1). All patients provided written, informed consent for this 
study, which was approved by the Central Institutional Review Board of the Georgia 
Institute of Technology (protocol number H16135) and adhered to the tenets set forth in 
the Declaration of Helsinki. These specimens were processed with a cell strainer 
(pluriSelect) to remove solid tissue and large cell aggregates greater than 20um in size 
(Figure 1.2). Cells were collected via centrifugation (Figure 1.3) and resuspended in flow 
buffer containing 35% Percoll, 1% BSA, 1% EDTA and 0.006% Tween in PBS[-,-] and 
pumped through our device at a total flow rate of 50 ul/min (Figure 1.4). Cells were then 
collected from the outlets and frozen at -80 ºC for sequencing analysis. Genomic DNA was 
then isolated from the sorted cells using a Nucleospin Tissue kit (Machery-Nagel). Next 
Generation Sequencing (NGS) libraries for sequencing TP53 were prepared using an 
Accel-Amplicon Comprehensive TP-53 kit (Swift Biosciences) (Figure 5.5). Samples were 
then barcoded using unique adapter sequences, pooled and sequenced on a single micro 
flow cell of an Illumina MiSeq (Figure 5.6). A known disease-causing mutation (c.455dup) 
was observed in the sequencing data of both patients along with wild type reads.  
3.3.5 Ascites Sorting for Immunocytochemistry 
Primary ascites specimens were obtained from one patient from Northside Hospital 
(Atlanta, Georgia) under an approved Institutional Review Board (IRB H16135) (Figure 
5.1). This specimen was processed with a cell strainer (pluriSelect) to remove solid tissue 
and large cell aggregates greater than 20 um in size (Figure 5.2). Cells were collected via 
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centrifugation (Figure 5.3) and resuspended in flow buffer (35 % Percoll, 1 % BSA, 1% 
EDTA and Tween in PBS[-,-]) and pumped through our device at a total flow rate of 27.5 
ul/min (Figure 5.4). Cells were collected from the device outlets and spun onto coverslips 
and fixed using 4% paraformaldehyde (PFA) for 10 minutes at room temperature. The 
fixed cells were permeabilized by incubating the cells in 0.1% Triton X-100 in PBS for 10 
minutes at room temperature. The permeabilized cells were then incubated in blocking 
solution containing 1% BSA, 22.52 mg/ml glycine and 0.1% Tween-20 in PBS to block 
non-specific interactions. The cells were finally incubated in a 1:100 dilution of the mouse 
monoclonal primary antibody against transglutaminase 2 (ab2386, Abcam) for 1 hour at 
room temperature and then incubated in a 1:200 dilution of the donkey polycolonal 
secondary antibody against mouse IgG (ab150105, Abcam) for 1 hour at room temperature. 
Finally, the cells were counterstained using Hoechst. The cells were then imaged using an 
imaging plate reader (Biotek) and the relative brightness of each cell was quantified using 
the plate reader software. 
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Figure 5. Sorting of primary ascites samples. An outline of the ascites sorting 
experiment: 1) Ascites containing nonmalignant cells (blue), cell aggregates, malignant 
cells (orange) and cell debris (grey) were collected from a patient. 2) Debris and aggregates 
were removed by filtration. 3) Cells were collected from the ascites via centrifugation. 4) 
Malignant cells were sorted from normal cells using our microfluidic platform. 5) The 
TP53 gene was selectively amplified from the genomic DNA isolated from each sorted 
fraction. 6) The proportion of cancer cells present in a sorted fraction was assessed by 
measuring the fraction of mutant reads present in the TP53 gene of genomic DNA isolated 
from each sample. 
3.4 Results 
The purpose of this study was to develop a microfluidic device capable of sorting 
metastatic ovarian cancer cells from liquid patient samples by leveraging biomechanical 
differences between target cancer cells and contaminating nonmalignant cells. As depicted 
in Figure 6, the device has 3 input ports, one for cells flanked by two for sheath liquid, 
which were used to organize the cells into a narrow stream aimed at the ‘top’ edge of the 
ridges. After entering the device, cells traveled through a rectangular microchannel 
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containing periodic diagonal constrictions. Larger, stiffer cells tended to translate along the 
constrictions (down in Figure 6) towards outlets 1-3, whereas smaller, softer cells simply 
passed through to outlets 4-5. Therefore, cells with different biomechanical properties were 
directed towards different outlets, of which there were 5 in total. Performance of this device 
for a given application depended on careful selection of device geometry and flow rate in 
order to find a productive balance between hydrodynamic and mechanical forces operating 
on the cell. Generally, the mechanical contribution to cell trajectories can be increased by 
decreasing the size of the gap between the bottom of the ridges and the floor of the channel 
whereas the hydrodynamic contribution to cell trajectories can be increased by increasing 
the flow rate. When hydrodynamic forces dominate, either by selecting too large of a gap 
size or too high of a flow rate, the cells will simply follow the streamlines in the device and 
no sorting will occur. If mechanical forces dominate, either through selection of too small 
of a gap size or too low of a flow rate cells will not be able to transit the constrictions and 
clogs will occur that prevent successful operation of the device. 
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Figure 6. Device Overview. The device consists of three inlets and five outlets connected 
by a sorting channel. Sheath fluid is pumped into the outer two inlets in order to focus the 
cells from the center inlet to their desired initial lateral position in the device, which in this 
application was the ‘top’ edge of the ridges (the side of the ridges closest to outlet 5). The 
cells then flow into the sorting chamber, where they interact with periodic diagonal 
constrictions (inset) which are designed to force cells to deform in order to pass under 
them. Large, stiff cells will tend to translate along the ridge (down in the figure, towards 
outlets 1-3) whereas small, soft cells will pass under the ridges without deflecting and be 
collected in outlets 4-5. 
Our first objective was to optimize the sorting device to be sensitive to the mechanical 
differences between ovarian cells with varying malignancy. We used high speed 
microscopy analysis to track cell lines of varying metastatic potential. As shown in Figure 
7, at a total flow rate of 30 µl/min differences in deflection between nonmalignant (IOSE) 
and malignant (HEY, HEY-A8 and OVCAR-3) cell types were observed. In addition, a 
substantial difference in cell trajectory was observed between cell lines with low 
(OVCAR3) and high (HEY-A8) metastatic potential. Therefore, biomechanical sorting 
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was sensitive to mechanical differences between ovarian cancer cells of different metastatic 
potential. The dynamic range of the separation was not sufficient to substantially isolate 
HEY and HEY-A8 cells in this configuration.  
 
Figure 7. Trajectory analysis of ovarian cancer cell lines. A) Characteristic trajectories 
of a metastatic ovarian cancer cell line (HEY) vs a nonmetastatic ovarian cancer cell line 
(IOSE) B) Migration assay showing the relative invasiveness of the HEY and OVCAR-3 
cell line. C) The trajectories of a variety of ovarian cancer cell lines analyzed to show the 
cumulative cell deflection at each ridge.  Cells with a lower metastatic ability (IOSE, 
OVCAR3) deflected more than cells with a higher metastatic ability (HEY, HEY-A8) 
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After finding that the cell trajectories demonstrated the device’s sensitivity to mechanical 
differences between ovarian cancer cell lines with differences in metastatic potential, we 
set out to establish that cell types of different metastatic potential can be separated. 
OVCAR-3 and HEY-A8 cells were labeled, mixed and infused into the device. The cells 
were sorted into 5 different outlets. As shown in Figure 8, a majority of the OVCAR-3 cells 
translated towards the stiff outlet (Outlets 1 & 2) while the HEY A8 cells translated into 
soft outlets (Outlets 4 & 5). From flow cytometry analysis of the sorted subpopulations, 
the enrichment factor of the target cell type was calculated using the following equation: 
(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑋 𝑐𝑒𝑙𝑙𝑠 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑌 𝑐𝑒𝑙𝑙𝑠)⁄
𝑂𝑢𝑡𝑙𝑒𝑡
(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑋 𝑐𝑒𝑙𝑙𝑠 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑌 𝑐𝑒𝑙𝑙𝑠⁄ )𝐼𝑛𝑙𝑒𝑡
 
As shown in Figure 8, the enrichment factor for HEY-A8 cells increased from outlet 1 to 
4 while the enrichment factor for OVCAR-3 cells decreased from outlet 1 to 4 Thus, 
OVCAR-3 cells were highly enriched at outlet 1 and HEY-A8 was highly enriched at outlet 
4. Specifically, we were able to achieve enrichment factors of ~100-fold for OVCAR-3 
and ~6-fold for HEY-A8. Very few cells were sorted into outlet 5 where only the smallest 
and softest cells would be expected. 
 43 
 
Figure 8. Sorting of ovarian cancer cell lines. In order to assess if our platform was 
capable of sorting cells with varying degrees of metastatic potential, we used our device to 
separate highly invasive cells (HEY-A8) from noninvasive cells (OVCAR-3). We were 
able to achieve enrichment factors of ~100-fold for OVCAR-3 and ~6-fold for the softer 
HEY-A8. Outlet 5 contained relatively few cells and would not be used in a clinical 
application. 
A sensitivity analysis was performed on the sorted populations of metastatic HEY-A8 cells 
and less metastatic OVCAR-3 cells to evaluate the accuracy of biomechanical sorting. The 
number of cells at various outlets were divided based on the conditions as shown in the 
confusion matrix (Figure 9A). Further, Figure 9A shows the true positive (TP), false 
positive (FP), true negative (TN) and false negative (FN) corresponding to all five outlets, 
as determined from the outlet of the device (condition) and flow cytometry analyses of cell 
stains (test). The number of HEY-A8 cells was considered as TPs for outlets 4 and 5 while 
the number of OVCAR-3 cells were considered to be TPs for outlets 1 and 2.  
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. Sorting with high sensitivity indicates that most of the 
desired cells have been collected at a particular outlet. As shown in Figure 8, most of the 
softer cells (HEY-A8) have been collected at outlets 4 or 5 and most of the stiff cells 
(OVCAR-3) have been collected at outlets 1 or 2.  




.  A sorting experiment with high specificity indicates that 
most of the non-desired cells at the corresponding outlets have not been sorted at the outlet. 
For example, most of OVCAR-3 cells have not been collected at outlets 4 and 5, and most 
of HEY-A8 cells have not been collected at outlets 1 and 2. Accuracy is the proportion of 
true cells (TPs or TNs) in a sorted population. It indicates the degree of veracity of the 
sorting test, defined by the equation 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =
𝑇𝑁+𝑇𝑃
𝑇𝑁+𝑇𝑃+𝐹𝑁+𝐹𝑃
. Figure 9B shows the 
calculated sensitivity, specificity and accuracy for 3 trials of cell separation using the 
microfluidic device and evaluating several outlet combinations. The separation with the 
device has a maximum sensitivity of 0.67, specificity of 0.99, and accuracy of 0.84.  
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Figure 9.  Sensitivity, specificity and accuracy analysis. A) Definitions of true positive, 
true negative, false positive and false negative used for our sensitivity analysis. B) The 
sensitivity, specificity and accuracy of sorting cells using our platform for each outlet, as 
well as for combinations of some neighboring outlets. The cell line in parentheses in the x 
axis label indicates which cells were considered true positives in the analysis. 
To determine if microfluidic sorting is capable of separating cell populations of clinical 
interest from heterogeneous specimens, we obtained ascites from two patients with 
advanced metastatic ovarian cancer from Northside Hospital in Atlanta, GA under an 
informed consent IRB protocol (H16135). Cells were resuspended in flow buffer and 
subjected to biomechanical sorting. The sorted fractions were collected from each of the 5 
output ports and were stained for TG2, a protein whose overexpression has been shown to 
be a feature of ovarian cancer [149]. This sorting resulted in cell fractions enriched for 
high-TG2 cells, consistent with an enrichment of metastatic cancer cells (Figure 10). In 
addition, next-generation sequencing (NGS) libraries were prepared to enable deep 
sequencing of the TP53 gene, mutations in which are commonly observed in ovarian cancer 
[150]. As shown in Figure 10, the proportion of mutant reads and TG2 florescence intensity 
in the sorted populations change at different device outlets indicating separation of the 
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heterogeneous input into biologically relevant subpopulations. Mutations in P53 were 
enriched at outlets 1 and 2 , whereas in outlets 4 and 5, cells containing P53 mutations were 
substantially removed, indicating a transfer of cancer cells to outlets 1 and 2. These results 
were consistent for both patients and indicate that the microfluidic cell sorting device is 
capable of selectively enriching cells with TP53 mutations associated with ovarian cancer 
cells in a label-free manner. A surprising feature of this result is that the cancer cells were 
enriched in outlets 1-2 for the primary cell sort, where metastatic cancer cells were enriched 
in outlets 3-4 in our cell line experiments. We believe this occurred because the cell line 
isolation was driven by differences in stiffness whereas the primary cell sorting was driven 
by differences in cell size. In the cell line experiment both cell lines were of similar size, 
but the cells with higher metastatic ability were softer, leading to them being sorted into 
outlets 3-4. In the primary cell experiment we believe sorting was driven by differences in 
cell size, where our cells of interest (CTCs) were larger than contaminating blood and 
immune cells. Therefore, our larger cells of interest deflected more than the smaller 
contaminating cells, resulting in enrichment of our cancer cells in outlets 1-2.  
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Figure 10. Sorting of Primary Ascites Samples. To assess the usefulness of our platform 
in a clinical setting, we used our device to sort metastatic cells from patient ascites samples. 
Enrichment of putative cancer cells (TP53 mutant, high TG2 intensity) was achieved in 
outlet 1 and 2 for A) one patient as quantified via immunocytology and B) two separate 





Personalized medicine is an exciting opportunity in cancer treatment that promises to 
increase the effectiveness of cancer therapy by accounting for differences between each 
patient's specific disease. However, application of personalized medicine depends on the 
clinician’s ability to identify the specific characteristics of a patient's cancer cells. The 
collection of a minority of tumor cells from complex liquid biopsies has been proposed as 
an effective yet minimally invasive approach to collecting metastatic cells from patients 
for testing. However, for testing to be economically feasible, technologies are required to 
perform high-throughput sorting of cancer cells from patient samples. Alternatively, it is 
possible to use high-cost next generation sequencing methods to analyze rare subsets of 
tumor cells, but a much higher sequencing depth, at greater cost, will be required unless an 
enrichment strategy is utilized. By simply examining the contents of the enriched ‘cancer’ 
outlet post-sort, our device can potentially serve as a diagnostic tool, as the cancer burden 
could be examined by the ratio of cancer to noncancer cells present in a sample. Further, 
functional or drug-sensitivity assays are also possible to examine isolated cells during 
downstream testing of pharmacological agents [151], [152]. Current 'gold standard' sorting 
techniques rely on expensive antibody-based conjugation of fluorescent markers or 
magnetic beads to the cells. Antibody-based strategies may affect the behavior of cells in 
downstream testing, whereas label-free approaches cause relatively little change to sorted 
cells. In addition, current gold standard technologies are particularly difficult to apply to 
the problem of ovarian cancer due to the lack of specific extracellular markers.  
In this work, we have demonstrated a label-free, high throughput sorting platform for the 
isolation of malignant cells from primary ascites samples. We have shown that our device 
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is sensitive to ovarian cancer cell lines with various degrees of metastatic potential and 
performed extensive characterization of our ability to sort these cell lines. Finally, we have 
demonstrated our ability to specifically enrich metastatic cancer cells from liquid patient 
samples, both by staining for the protein marker TG2 and by quantifying mutations in the 
cancer repressor gene TP53. Our platform constitutes an enabling step for the testing of 
metastatic cells for personalized medicine applications. By cheaply and quickly isolating 
metastatic cells from complex patient samples, we will enable downstream assays for drug 
response and functional assays as well as point-of-care diagnostics. 
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CHAPTER 4. LABEL-FREE MICROFLUIDIC ENRICHMENT 
OF PHOTORECEPTOR CELLS 
4.1 Abstract 
Inherited retinal degenerative disorders such as retinitis pigmentosa and Usher syndrome 
are characterized by progressive death of photoreceptor cells. To restore vision to patients 
blinded by these diseases, a stem cell-based photoreceptor cell replacement strategy will 
likely be required. Although retinal stem cell differentiation protocols suitable for 
generating photoreceptor cells exist, they often yield a rather heterogenous mixture of cell 
types. To enrich the donor cell population for one or a few cell types, scientists have 
traditionally relied upon the use of antibody-based selection approaches. However, these 
strategies are quite labor intensive and require animal derived reagents and equipment that 
are not well suited to current good manufacturing practices (cGMP). The purpose of this 
study was to develop and evaluate a microfluidic cell sorting device capable of exploiting 
the physical and mechanical differences between retinal cell types to enrich specific donor 
cell populations such as Retinal Pigment Epithelial (RPE) cells and photoreceptor cells. 
Using this device, we were able to separate a mixture of RPE and iPSC-derived 
photoreceptor precursor cell lines into two substantially enriched fractions. The enrichment 
factor of the RPE fraction was 2 and that of the photoreceptor precursor cell fraction was 
2.7. Similarly, when human retina, obtained from 3 independent donors, was dissociated 
and passed through the sorting device, the heterogeneous mixture could be reliably sorted 
into RPE and photoreceptor cell rich fractions. In summary, microfluidic cell sorting is a 
promising approach for antibody free enrichment of retinal cell populations. 
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4.2 Introduction 
Inherited retinal degenerative diseases such as retinitis pigmentosa, Leber congenital 
amaurosis and Usher syndrome are collectively a major cause of incurable blindness in the 
developed world. A unifying feature of this group of disorders is progressive death of the 
light sensing photoreceptor cells of the outer neural retina. These diseases are genetically 
very heterogeneous and as a result many specific treatments will likely be required to treat 
patients affected with them. For example, of the more than 40 different genes that have 
been reported to cause retinitis pigmentosa, only a few cause more than 1% of the disease 
in the total population [92]. 
For patients who receive a molecular diagnosis early in the course of their disease and still 
have a large number of photoreceptor cells remaining, it may be possible to restore gene 
function and prevent disease progression with some form of viral or nanoparticle-mediated 
gene replacement. To evaluate the efficacy of such gene-based therapeutics, scientists have 
traditionally relied upon the use of animal models. Unfortunately, for many retinal 
degenerative disorders, animal models that faithfully recapitulate critical aspects of the 
disease phenotype do not exist. For instance, structural differences between human and 
non-primate photoreceptor cells have resulted in rodent models of Usher syndrome that fail 
to develop retinal degeneration [153]. To overcome this problem some investigators are 
beginning to employ patient-derived induced pluripotent stem cell (iPSC) culture systems. 
By using patient-derived iPSCs to generate retinal neurons, either as 3D laminated 
organoids [12], [17], [20], [154] or as a 2D monolayer of cells [14], [155], one can often 
identify disease specific phenotypes that can be used to evaluate treatment efficacy [17], 
[92], [97], [156], [157]. A limitation of this approach is that stem cell differentiation 
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protocols often yield a rather heterogenous mixture of cell types. Thus, to be able to 
evaluate therapeutic efficacy in a single cell population such as human photoreceptor cells, 
some type of cell isolation or enrichment method is often needed. 
For patients with advanced retinal degenerative disease, who have lost the majority of their 
photoreceptor cells, restorative stem cell-based photoreceptor cell replacement will likely 
be required. For this approach, the need for cellular enrichment is even greater. 
Specifically, as many patients with inherited retinal degeneration retain both RPE and inner 
retinal neurons for years after complete loss of their photoreceptor cells [158], 
photoreceptor cell enrichment methods that reduce the number of unneeded RPE and inner 
retinal neurons in the transplanted cell population would be useful. To date, scientists have 
primarily used antibodies to cell surface antigens coupled with magnetic bead pull down 
or fluorescence activated cell sorting (FACS) to enrich specific cell types in a 
heterogeneous mixture [56], [57], [159], [160]. Although potentially useful, these 
approaches require the use of expensive reagents and equipment that are not ideally suited 
for current good manufacturing practices (cGMP). In addition, for applications such as 
isolating photoreceptors from a mixed population of retinal cells, reliable extracellular 
markers may not exist. 
In this study, we demonstrate the use of a novel microfluidic cell sorting device to perform 
antibody-free sorting of a mixed population of retinal cells into biologically meaningful 
fractions. The microfluidic device itself is biologically inert and sorts cells based on their 
mechanical and physical properties and thus does not require the use of antibodies or 
similar non-cGMP-compliant reagents [148], [161]. In our hands the use of similar devices 
have little impact on cell viability [2]. The device itself is quite small, making it readily 
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useable within standard biological safety cabinets in existing cGMP spaces. In addition to 
being useful for disease modelling purposes, this approach could also be used for cGMP-
compliant purification of patient-derived retinal cells in regenerative medicine 
applications. 
4.3 Methods 
4.3.1 Human iPSC derived photoreceptor precursor cell line generation and culture 
Retinal progenitor cells were generated as previously described [12], [13]. In brief, as per 
Fig. Figure 11A, iPSCs, derived from a normal non-diseased individual, were maintained 
on recombinant human laminin 521 coated tissue culture plates and fed with Essential 8 
medium supplemented with rhFGF2. For 3-D differentiation, hiPSCs were passaged with 
TrypLE, centrifuged, and resuspended in 3-D differentiation medium supplemented with 
Y-27632 ROCK inhibitor and IWR1e. From this suspension, 1 × 104 cells were added per 
well to a 96 well ultra-low adhesion tissue culture plate. On days 2–10, the 3-D 
differentiation media was supplemented with 1% ECM. On day 12, spheres were 
transferred to 100 mm ultralow attachment culture dishes. On days 14–17, the 3-D 
differentiation medium was supplemented with 1% ECM mixture, 40 nM CHIR99021, and 
100 nM SAG. On day 18, the media was switched to neural retina medium. At day 45, 30–
50 spheres were dissociated using Accutase. Cell suspensions were then counted and plated 
on Matrigel coated wells. For immortalization, 24 h after plating, cells were washed with 
fresh neural retina media and transduced with a lentiviral cocktail containing vectors 
driving CRX (Figure 11B) and NRL (Figure 11C) to induce photoreceptor cell fate 
commitment, and GRK1 promoter driving hTERT (Figure 11D) for immortalization. Five 
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days following transduction, immortalized photoreceptor precursor cells were 
pharmacologically selected via blasticidin selection (2 μg/ml for 14 days). Immortalization 
was achieved via CRX/NRL induced activation of the GRK1 promoter, which in turn 
drives hTERT expression. 
 
Figure 11. Method for generating iPSC-derived photoreceptor precursor cell line. A-
D: Schematic diagrams depicting the methods used for iPSC-PPC line generation (A) and 
the lentiviral vectors used for forced expression of CRX (B), NRL (C) and cell line 
immortalization (D).  
4.3.2 Lentiviral vector generation 
Lentiviral vectors were generated in a stepwise fashion. The EF1 alpha promoter and 
GRK1 promoter were subcloned in the pENTR™ 5′-TOPO™ vector. HTERT, CRX, and 
NRL were subcloned into the pENTR™/D-TOPO™ vector. Then using LR clonase, three 
lenti viral vectors were generated: 1) GRK1p-hTERT, 2) EF1alpha- NRL, and 3) 
EF1alpha- CRX. Of note, both EF1alpha- NRL and EF1alpha- CRX vectors contained the 
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MPGK promoter driving blasticidin resistance cassette which was used to select for 
transduced cells. 
4.3.3 Immunocytochemical analysis 
ARPE-19 and human iPSC-derived photoreceptor precursor cells (hiPS-PPCs) were fixed 
in 4% PFA and stained using our previously published protocols [12]. ARPE-19 cells were 
stained using mouse anti-MITF (Exalpha Biologicals), mouse anti-RPE65 and mouse anti-
ZO1 (Thermo Fisher) antibodies. HiPS-PPCs were stained using goat biotinylated-anti-
OTX2 (R&D Systems), goat biotinylated-anti-NRL (R&D Systems), mouse anti-rhodopsin 
(EMD Millipore), sheep anti-CRX (R&D Systems), rabbit anti-rabbit NR2E3 (EMD 
Millipore), and rabbit anti-recoverin (EMD Millipore) antibodies. Primary antibodies were 
detected using the species-appropriate, fluorescently conjugated Alexa Fluor secondary 
antibodies [Life Technologies/Thermo Fisher Scientific; goat anti-mouse 488, goat anti-
rabbit 568, Streptavidin 647 and donkey anti-sheep 647]. Cell nuclei were counterstained 
using DAPI. Cells were imaged using a Leica DM 2500 SPE confocal microscope (Leica 
Microsystems). 
4.3.4 AFM and force curve analysis 
To obtain global stiffness measurements of each cell line, 7.32 μm spherical polystyrene 
particles were attached to tipless silica nitride cantilevers (Bruker Probes) using a two-part 
epoxy, which was dried overnight prior to use. To characterize the mechanical properties 
of each cell, we used force spectroscopy to obtain force-indentation curves with an atomic 
force microscope (AFM) (Asylum Research) with an integrated optical microscope 
(Nikon) on a vibration isolation table using our previously published protocols [137], 
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[162]. Before each day of measurements, the AFM was calibrated by taking a single force 
curve on a clean FluoroDish (World Precision Instruments) to determine the deflection 
inverse optical lever sensitivity (i.e., the voltage read in the photodetector for a given 
amount of cantilever deflection) for each cantilever. Next, the Sader calibration method 
was used to obtain cantilever spring constants (k is approximately 5–20 pN/nm) based on 
the thermal vibration of the cantilevers. For cell measurements, the cantilever probe was 
visually aligned with the cell center and moved with a velocity of 1 μm/s to indent the cell 
with increasing compressive force until a force trigger of 10 nN was reached. The 
cantilever was held in position for 10 s to allow viscous relaxation of the cell before 
reversing the direction of the cantilever's velocity. 
We calculated the cellular reduced Young's modulus [163] based upon the Hertzian model 
of non-adhesive elastic contact between two bodies. The contact point was estimated by 
the intersection of the flat, undeformed region of the force curve with a line fit to the region 
of the force curve corresponding to the cantilever's contact with the cell. Next, we identified 
the true contact point by iteratively testing the points around the estimated contact point 
with the minimal residual difference between the measured force curve and a non-linear fit 
described by the governing Hertz contact mechanics equation between an elastic sphere 
and an elastic half space. We additionally fit the dwell region of the force curve to a 
biexponential decay curve to identify fast and slow viscous time constants [164]. 
4.3.5 Human donor retina dissociation 
Human donor eyes were acquired through the Iowa Lion's Eye Bank, with consent from 
the donors' next of kin and in full accordance with the Declaration of Helsinki. For each 
 57 
donor, 8-mm trephine punch biopsies were acquired and retina, RPE, and choroid was 
dissected away from the underlying sclera. Retinal, RPE and choroidal tissue were pooled 
and incubated in 20 units/mL of papain with 0.005% DNase (Worthington Biochemical 
Corporation, Lakewood NJ) for 1.25 h at 37 °C with gentle agitation. Dissociated cells 
were filtered through a 70 μm filter to remove aggregates before resuspension in PBS [+,+] 
containing 0.1% BSA, 30% Percoll, 0.006% Tween-20 and 100U/mL DNAse I. Cells were 
resuspended to a concentration of 5–10 million cells/mL using the Countess II FL 
Automated Cell Counter (ThermoFisher Scientific, Waltham MA) before cell sorting. 
4.3.6 Quantitative RT-PCR 
Cell type specific transcript expression was assessed using TaqMan probes targeted against 
BEST1, RPE65, recoverin, rhodopsin, PKCα and POU4F2 (Life Technologies/Thermo 
Fisher Scientific). Total RNA was isolated using Trizol (Life Technologies/Thermo Fisher 
Scientific) according to manufacturer's instructions. One microgram of RNA was reverse 
transcribed using the Superscript VILO cDNA Synthesis Kit (Life Technologies/Thermo 
Fisher Scientific; Cat #: 11754050). Quantitative RT-PCR was performed using a 
QuantStudio 6 Flex Real-time PCR system (Life Technologies/Thermo Fisher Scientific). 
A probe set targeting beta-actin was used as a loading control. 
4.3.7 Microfluidic device fabrication and cell sorting 
Devices were manufactured using standard soft lithography techniques to cast PDMS on 
molds consisting of SU-8 photoresist patterned on silicon wafers, as described previously 
[151], [152]. The size of the gap between each ridge and the surface of the device (see 
Figure 12) was selected based on measured cell size. For the cell line sorting experiments, 
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a device with 9 μm gaps was fabricated. For the human retina sorting experiments, a device 
with 2 μm gaps was fabricated. The dimensions of the mold ridge heights were measured 
with profilometry (Dektak 150 profiler) and optical microscopy. Five outlet devices were 
tested to evaluate the accuracy of fractionation of the heterogeneous cells to isolate target 
retinal cell types. The mold pattern was translated to polydimethylsiloxane (PDMS), inlet 
and outlet holes were punched with biopsy punch, and the chip bonded to glass. Cells were 
transferred to a syringe and infused into the microfluidic device through Teflon tubing 
using a syringe pump (PHD 2000, Harvard Apparatus, and BS-300, Braintree Scientific) 
at specified flow rates (15-45 μl/min). In experiments in which cell trajectories were 
recorded, an inverted bright-field microscope (Eclipse Ti, Nikon) was used equipped with 
a high-speed camera (Phantom v7.3, Vision Research) [88], [89], [165]. In experiments on 
fluorescently labeled cell lines, cells were labeled with CellTracker™ deep red (ARPE-19) 
and green (hiPS-PPCs) (Molecular Probes Inc.) according to manufacturer protocols. After 
loading the cells with the dye, the accuracy of sorting could be quantified using flow 
cytometry (BD Biosciences, LSR II). 
4.4 Results 
4.4.1 Design and optimization of a microfluidic retinal cell sorting device 
The purpose of this study was to develop a microfluidic device, capable of exploiting 
differences in mechanical and physical properties of retinal cells, to enrich for specific cell 
types. As depicted in Figure 12, this device was designed with 3 input ports, one for loading 
a mixed cell population and the remaining two for injection of sheathing fluid to generate 
flow through the center of the device. The input ports are connected to a flight path chamber 
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with a number of diagonal fins separated from the base by small gaps that serve to channel 






Figure 12. Microfluidic cell sorting device designed for sorting of retinal cells. A: 
Schematic diagram depicting the design of the microfluidic cell sorting device. B: Phase 
micrograph of the cell sorting device flight path – area containing diagonal ridges designed 
to deflect cells to the left or right side of the device based on each cell's size, modulus, and 
viscosity. Upper panel scale bar = 1 mm. Lower panel scale bar = 400 μm. C: Photograph 
of a cell sorting device demonstrating its size and design. 
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Our first goal was to determine whether RPE cells could be separated from iPSC-derived 
photoreceptor precursor cells. In order to determine the degree of enrichment that results 
from passage through the device, it is necessary to know the exact proportion of each cell 
type in the starting population. Human iPSC derived retinal organoids and samples of 
primary retinal tissue both vary in the percentage of each cell type present and are therefore 
less suitable for this experiment than homogeneous stable cell lines. Although several 
excellent immortalized human RPE cell lines exist (e.g., ARPE-19 and hTERT RPE-1), 
similar photoreceptor precursor cell lines are not available. As such, for these experiments 
a photoreceptor precursor cell line (hiPS-PPC) was generated as per the methods section. 
As expected, the transgenes CRX and NRL were robustly expressed following lentiviral 
transduction (Figure 13A). As shown in Figure 13B, expression of the retinal progenitor 
cell marker SOX2, and the photoreceptor cell markers S Opsin, M/L Opsin, RP1, recoverin 
and RPGR ORF15 was detectable via rt-PCR in cultures of immortalized human iPSC-
derived photoreceptor precursor cells for at least 20 passages. Likewise, the photoreceptor 
precursor cell markers OTX2 (Figure 13C) and recoverin (Figure 13D), and the rod 




Figure 13. Generation of a stable human iPSC-derived photoreceptor precursor cell 
line. A: rt-PCR analysis performed using RNA isolated from human iPSC-PPCs following 
lentiviral transduction. B: rt-PCR analysis performed using RNA isolated from human 
donor retina (hRetina) as a control and iPSC-PPCs. POLR2A was included as a loading 
control. C-E: Immunocytochemical analysis of immortalized hiPS-PPCs using antibodies 
targeted against OTX2, recoverin and rhodopsin. 
To determine whether this newly generated iPSC-derived photoreceptor precursor cell line 
and the commonly used RPE cell line, ARPE-19, differed enough in their mechanical 
properties to be sorted using our device, we first measured the stiffness and viscosity of 
each line using atomic force microscopy (AFM) (Figure 14A–B). As shown in Figure 14, 
ARPE-19 cells are smaller (C), slightly stiffer (D) and more viscous (E & F) than human 
iPSC derived photoreceptor precursor cells (hiPS-PPCs), suggesting that these populations 
could be different enough to be sortable using this microfluidic approach. 
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Figure 14. Mechanical characterization of retinal cell lines. A: Representative phase 
micrograph depicting the AFM probe as it approaches cells for mechanical analysis. B: 
force curves obtained following mechanical analysis of ARPE-19 (blue lines) and hiPS-
PPCs (red lines). C: Area of ARPE-19 and hiPS-PPCs as they approach and pass beneath 
each ridge within the device as measured via high speed microscopy. D: Modulus (Pa) of 
ARPE-19 and hiPS-PPCs. E-F: Fast and slow time constant (i.e. measure of viscosity) for 
ARPE-19 and hiPS-PPCs. Collectively these data show that human ARPE-19 cells are 
smaller, stiffer and less viscous than human hiPS-PPCs 
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To determine the optimal conditions for sorting and to evaluate the degree of enrichment, 
ARPE-19 and human iPSC-derived photoreceptor precursor cells were first injected 
individually into the sorting device via a syringe pumped at a constant rate of either 15 
μL/min, 30 μL/min or 45 μL/min. Cellular trajectories were tracked for each cell line using 
high-speed microscopy and the characteristic deflections that occurred as the cells passed 
beneath each ridge of the device are shown in Figure 15. The slowest injection rate, 15 
μL/min, resulted in the greatest variability in per ridge deflection (Figure 15A). This 
variability was much less when cells were injected at a constant rate of 45 μL/min, but at 
this rate, the difference in mean cumulative deflection between the two cell lines was the 
smallest of the 3 injection rates tested (Figure 15C). The greatest difference in 
characteristic deflections between the two cell lines and the smallest variability in per ridge 
deflection was seen at a flow rate of 30 μL/min (Figure 15B). Thus, this injection rate was 
chosen for the subsequent cell-line enrichment experiments. 
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Figure 15. Optimization of cell enrichment parameters. A-C: Ridge induced deflections 
as a function of injection speed (A = 15 μL/min, B = 30 μL/min, C = 45 μL/min). The 
largest cumulative deflection difference with least amount of overlap between ARPE-19 
and iPS-PPCs was detected at a constant injection rate of 30 μl/min (B). Note: the box 
marks the limits of the 1st and 3rd quartile, the line within the box represents the median 
and the whiskers represent the maximum and minimum values detected. 
4.4.2 Separation of RPE and iPSC-derived photoreceptor precursor cell lines via 
microfluidic cell sorting. 
To test whether the device could be used to enrich for specific retinal cell populations, 
ARPE-19 and hiPS-PPCs were fluorescently labeled and then mixed at a 1:1.7 ratio and 
injected through the device via a syringe pump at a constant rate of 30 μL/min. As indicated 
above, knowing the precise makeup of the starting population (i.e., 37% ARPE-19 and 
63% iPS-PPCs) was critical in order to determine the enrichment factor for each cell type 
at each of the device's output ports. 
 66 
 
As shown in Figure 16, at these conditions we were able to achieve enrichment values of 
2 for ARPE-19 and 2.7 for hiPS-PPCs. Specifically, outlet 1, which we predicted would 
contain larger cells with the greatest deflection rates, was heavily enriched for hiPS-PPCs. 
Outlet 4, which we predicted would contain smaller cells that had lower deflection rates 
was highly enriched for ARPE-19 cells. Outlet 5 had very few of either cell type. 
 
Figure 16. Sorting of ARPE-19 and hiPS-PPCs using a microfluidic cell sorting 
device. Following microfluidic cell sorting, outlet 1 contained the greatest number of hiPS-
PPCs and the lowest number of ARPE-19 cells (hiPS-PPCs enrichment factor = 2.75). 
Conversely outlet 4 contained the greatest number of ARPE-19 cells and the lowest number 
of hiPS-PPCs (ARPE-19 enrichment factor = 1.97). As outlet 5 did not contain a significant 
number of either cell type the enrichment factor was not plotted. 
  
 67 
4.4.3 Microfluidic sorting of mature human donor derived retinal cells 
To determine if a similar microfluidic cell sorting strategy could be used to sort mature 
retinal cells, new devices were fabricated that contained the same number of ridges but a 
ridge gap size of 2 μm, which was selected based upon the average size of all cell types 
that would be present in the input cell population. For this experiment, human donor eyes 
were dissected, the neural retinal and RPE cell layers were harvested, and the tissues were 
mixed and dissociated into a single cell suspension. As the contribution of each of the 
different retinal cell types in the starting population was unknown, it was not possible to 
calculate an enrichment factor in this experiment. Instead, quantitative RT-PCR using 
primers targeted against transcripts specific to several of the dominant retinal cell 
populations was performed on the fractions collected from each of the 5 output ports. As 
in the cell line sorting experiment described above, the dissociated heterogeneous input 
cell population was injected via a syringe pump at a rate of 30 μL/min. As shown in Figure 
17, expression of RPE, photoreceptor and inner retinal cell markers varied based on outlet, 
indicating separation of the heterogeneous input into biologically relevant subpopulations. 
Specifically, cells expressing the RPE cell markers BEST1 (Figure 17A) and RPE65 
(Figure 17B) were most abundant in outlet 1. The abundance of these markers decreased 
dramatically in outlet 2, and little to no RPE marker expression was detected in outlets 3 
through 5. The photoreceptor cell markers recoverin (expressed in both rods and cones) 
and rhodopsin (expressed exclusively in rods), were virtually absent in outlet 1 (Figure 17C 
and D). While recoverin was expressed at equal levels in outlets 2 through 4 (Figure 17C), 
rhodopsin expression was increased in outlet 2 and was higher again in outlets 3 and 4 
(Figure 17D). Interestingly, both recoverin and rhodopsin were expressed at low levels in 
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outlet 5, similar to what was observed in outlet 1 (Figure 17C and D), indicating that most 
photoreceptor cells were captured in outlets 2, 3 and 4. In contrast to cultured cells, in this 
experiment the RPE cells are the largest and/or stiffest cells present in the input population. 
As such the finding that the larger, stiffest cells were deflected to the left toward outlets 1–
3 and the smaller and/or softer cells were deflected toward the right into outlets 3–5 held 
true. Expression of PKCα, a bipolar cell marker, was detected at low levels in outlet 1, 
increased to a similar level in outlets 2 and 3 and was detected at the highest levels in outlet 
4 (Figure 17E). The ganglion cell marker POU4F2 was detected at low levels across all 5 
outlets, with a slight skew toward outlets 1–3 (Figure 17E). Collectively, these data 
demonstrate that a microfluidic cell sorting device can be used to successfully enrich for 





Figure 17. Microfluidic sorting of retinal cells obtained from human donor eyes. A-
F: Quantitative RT-PCR analysis of human retina using primers targeting BEST1 (A), 
RPE65 (B), recoverin (C), rhodopsin (D), PKCα (E) and POU2F4 (F) following 
microfluidic cell sorting. N = 3 independent donors. Error bars = Standard deviation. DDCt 
was compared against BActin as a method to normalize for differences in cell number at 
each outlet. 
4.5 Discussion 
Currently, autologous cell therapies are under development for a wide variety of 
conditions, ranging from cancer to neurodegenerative blindness. As stem cell-based cell 
replacement strategies enter the clinic, sophisticated cell sorting technologies designed to 
enrich the donor cell population for the preferred cell types will be desirable [76], [146], 
[166]. This is especially true considering that the majority of current stem cell 
differentiation protocols are designed to recapitulate embryonic development and therefore 
give rise to a variety of organ specific cell types that may not be required for the target 
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application. For instance, retinal differentiation protocols are very effective in generating 
photoreceptor cells but also produce contaminating retinal cell types including retinal 
pigment epithelial cells and bipolar neurons. For the treatment of patients with 
photoreceptor cell specific diseases, such as retinitis pigmentosa, who often retain all other 
retinal cell types until very late in disease, transplantation of non-photoreceptor cells will 
likely be unnecessary [158] and possibly detrimental. 
The majority of the preclinical photoreceptor cell enrichment strategies published to date 
have been focused on identifying cell surface antigens and antibodies that can be used to 
capture specific cell populations using traditional ‘gold standard’ cell-sorting approaches, 
such as FACS and/or MACS. For instance, in 2012 Eberle and colleagues demonstrated 
that by using a primary antibody targeted against the cell surface antigen CD73, and a 
secondary antibody conjugated to MACS micro-beads, they could magnetically isolate 
with high efficiency rod photoreceptor precursor cells from dissociated neonatal mouse 
retinas [56]. Lakowski and colleagues later expanded on this work by identifying several 
other cell surface antigens, namely CD24, CD133 and CD47, that could be used in 
conjunction with CD73 to further enrich for transplantable photoreceptor precursor cells 
via FACS or MACS [57]. 
As efficient as FACS- and MACS-based enrichment approaches are, when cells are 
destined to be transplanted into patients, where all reagents and procedures must be 
guaranteed to be safe and reproducible in order to gain FDA approval, avoiding the use of 
antibodies and stains that can alter cell function and viability is desirable. Likewise, from 
a clinical production perspective, large specialized pieces of equipment such as FACS units 
that are difficult to adapt to cGMP conditions should be avoided when possible. Of interest, 
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one approach that has been used extensively by us and others for enrichment of specific 
cell populations post-differentiation, is drug based positive selection following lentiviral 
incorporation of an antibiotic resistance cassettes. For instance, in a recent study we 
demonstrated how puromycin antibiotic resistance delivered in a homology directed repair 
construct could be used to select patient derived iPSCs following CRISPR correction and 
differentiation [91]. This approach could readily be adapted to cGMP and modified to 
select for PPCs as described in this study. That said, antibiotic selection strategies are most 
appropriate when the specific target is well defined, as was the case both here for forced 
PPC production and in the above cited CRISPR report. The ideal retinal graft is unlikely 
to contain only one cell type. Rather a mixture of rods, cones (red, green and blue) and 
even support cells such as Müller glia, may be beneficial. In such a case, enrichment of late 
stage retinal progenitor cells that are capable of giving rise to all photoreceptor cell 
populations and glial cells would be ideal. With that in mind, the purpose of this study was 
to develop a method for enriching retinal cell populations based on the cells’ physical and 
mechanical characteristics (i.e., size, stiffness and viscosity) [76], [88], [89], [148], [166] 
rather than surface protein expression. The platform described in this study was designed 
such that cells are exposed to repeated compressions by a series of narrow gaps oriented 
diagonally to the direction of fluid flow. As cells interact with these gaps, which are chosen 
to be smaller than the cell's diameter, they deflect laterally to a degree that is related to their 
size and stiffness. The design of the gaps allows cell debris and aggregates to move along 
the diagonal fins into a gutter and to exit the device without causing clogs. 
As designed, the device selectively deflects larger softer cells to the left toward outlets 1 
and the smaller stiffer cells to the right toward outlet 5. The results of our two cell line 
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mixture experiment (Figure 16) led us to hypothesize that RPE cells would be deflected 
toward outlets on the left of the device (i.e., larger cells would be deflected into outlets 1–
3) and photoreceptor cells would be sorted into outlets on the right of the device (i.e., 
smaller cells would be deflected into outlets 3–5). As shown in Figure 17, the majority of 
human primary RPE cells were indeed sorted into outlet 1. A sharp decline in RPE cell 
message was detected in the cells in outlet 2 and almost no message was detected in the 
cells from outlets 3–5. Likewise, almost no photoreceptor cells, as determined by a lack of 
recoverin and rhodopsin expression, were sorted into outlet 1. Rather, there was an equal 
distribution of recoverin-positive cells (i.e. rods and cones) in outlets 2–4 and a sharp 
decline in recoverin expressing cells in outlet 5. Interestingly, the number of cells 
expressing rhodopsin (rod specific marker) steadily increased beyond outlet 2, with peak 
expression detectable in outlet 4. As with recoverin expression, rhodopsin expression 
sharply dropped in outlet 5. These findings suggest that rod photoreceptor cells are smaller 
or softer than cone photoreceptor cells as one would predict based on histopathology [167], 
[168]. It would also suggest that by selecting only cells in outlet 2 one would have a 
population that is enriched for cone photoreceptor cells, whereas outlet 4 would be more 
heavily skewed toward rod photoreceptor cells. Interestingly, inner retinal neurons 
expressing PKCα (i.e. bipolar cells) were skewed toward outlet 4, while POU4F2 
expressing cells (i.e. ganglion cells, which vary widely in size in the human retina) were 
distributed across all 5 outlets with a slight skew toward outlets 1–3 with lower numbers 
in outlet 4 and 5. Compared to RPE and photoreceptor cells, the amount of message 
attributed to these inner retinal neurons across all outlets was relatively low. We suspect 
that this is due to the fact that there are far fewer bipolar neurons and retinal ganglion cells 
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in the human retina than photoreceptor cells, and that more aggressive cellular dissociation 
techniques are required to liberate these cell types, which unlike the RPE are embedded 
within the inner plexiform and nerve fiber layers respectively. Regardless, from a cell 
replacement perspective, the fact that retinal ganglion cells, which during stem cell 
differentiation develop on the inner most surface of retinal organoids and often die before 
mature photoreceptor precursor cells are made [12], suggest that removal of this cell type 
will be less of a concern. Likewise, the numbers of bipolar cells generated and sustained 
during retinal differentiation is often low [12] and inclusion of a small number of bipolar 
interneurons in a photoreceptor cell replacement based-approach may actually be 
beneficial. 
In addition to the application discussed above, this platform also has applicability to other 
tissue types, including isolation of limbal stem cells from the limbal region of the eye [162], 
undifferentiated stem cells from differentiated stem cells [146], and cancer cells from liquid 
patient samples [137]. We also believe that the device described in this paper could be 
enhanced to improve throughput by parallelizing individual flow channels and that sorting 
sensitivity/specificity could be further improved through additional optimization. 
In summary, we believe that antibody-free sorting will be a favorable choice for clinical 
applications due to its low cost, high throughput and cGMP compatibility. In this work, we 
present a high-throughput, antibody-free platform capable of sorting pooled primary retinal 
cells into biologically relevant subpopulations. We have demonstrated that the device is 
sensitive to the differences between cell types common in the human retina, and thus should 
be capable of sorting cells desired for transplant from other, contaminating cell types. This 
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device represents a key technological advancement for the development of future cell 
therapies, including iPSC derived treatments for inherited retinal degeneration. 
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CHAPTER 5. USE MICROFLUIDICS TO DELIVER LARGE 
FUNCTIONAL CONSTRUCTS TO PATIENT-DERIVED IPSCS 
IN A ONE-STEP MECHANICAL PROCESS 
5.1 Abstract 
Autologous cell replacement therapies are at the forefront of recent efforts to treat patients 
with advanced inherited retinal degenerative blindness. While we and others believe it will 
be possible to use gene therapy to halt disease progression in patients who still have useful 
vision, treating patients who have already lost their sight will require cell therapies to 
replace tissue lost due to their condition. Recent advances in the manufacture of patient- 
derived photoreceptors is encouraging but has been hampered by a lack of technologies 
capable of efficiently delivering large macromolecules to patient-derived induced 
pluripotent stem cells (iPSCs). In this chapter, we will detail our effort to address this need 
using microfluidic devices capable of effecting convective delivery of large 
macromolecules to the interior of cells. In addition to detailing our progress to date, we 
will also describe our future plans to increase transfection efficiency by using multistage 
microfluidic systems to overcome the iPSC size heterogeneity that we have observed. 
5.2 Introduction 
In many forms of inherited retinal degenerative blindness, a disease-causing mutation 
causes photoreceptor cells to die over the course of a patient’s life, causing their vision to 
degenerate, eventually leading to blindness. While it is theorized that gene therapies 
designed to correct the causative mutation in a patient’s cells could halt the progression of 
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their disease, it is unlikely that this therapy will be effective in patients who have already 
lost most of their vision. In an attempt to develop treatments for these patients, we and 
others have been developing pipelines for the manufacture of patient-derived 
photoreceptors with the aim of eventually transplanting these cells into patients to replace 
the tissue they have lost and restore some of their vision [3]–[12]. While complicated in 
practice, the general approach can be described simply. First, fibroblasts are collected from 
a patient via a skin biopsy. Next, forced expression of several key transcription factors 
(OCT4, SOX2, KLF4 and C-MYC, commonly referred to as the Yamanaka factors) is used 
to transform these fibroblasts into iPSCs. While the resulting iPSCs could at this point be 
differentiated into patient-derived photoreceptors, they would still contain the mutation 
that caused the patient’s disease originally. Therefore, before differentiation, 
macromolecules must be delivered to the iPSCs to correct the patient’s disease-causing 
genetic variants. Genome editing of iPSCs has been achieved using a variety of different 
approaches (e.g., CRISPR, zinc finger nucleases, TALENs, etc.), all of which require some 
technology to facilitate their delivery to the cell’s interior [91]–[93]. After the patient’s 
disease causing mutation is corrected, the resulting iPSCs can be differentiated into patient 
derived photoreceptors suitable for transplant [12]–[42]. 
In order to be suitable for the correction of mutations in iPSCs destined for transplant after 
differentiation, transfection technologies must address two main challenges. First, any 
reagents used must be compatible with current good manufacturing practices (cGMP) and 
safe for use in human subjects. Second, they must be capable of delivering very large 
constructs at high efficiencies. The requirement that the technologies be safe is an obvious 
one, but it may be less clear why the use of large constructs is required. Current gene editing 
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technologies being considered for the correction of these mutations work in two steps. First, 
a double stranded DNA break within the cell’s genome is made using one of several 
technologies capable of cutting DNA at prescribed locations (typically within close 
proximity to the patient’s disease causing mutation) such as CRISPR, zinc finger nucleases 
or TALENs. After inducing this break in the genome, the cell’s own DNA repair machinery 
will attempt to repair the damage via either non-homologous end joining (NHEJ), which is 
often imprecise, or the more accurate homology directed repair (HDR). With HDR, the cell 
will use a template homologous to the sequence near the induced DNA damage to replace 
any missing sequence and repair the break. By co-delivering wild-type sequence spanning 
the patient’s mutation as a template, HDR can result in precise correction of the mutation 
in the cell’s genome [43]–[45]. Unfortunately, the sequences required for nuclease 
generation, genome targeting, and HDR are collectively quite long. For instance, a single 
multicistronic CRISPR HDR construct for correcting USH2A mutations in use in our 
laboratory is over 14kb in length. 
While many technologies such as electroporation, lipofection and viral transduction have 
been commercialized for delivering macromolecules to the interior of cells, none of these 
techniques are simultaneously cGMP compatible and capable of delivering large genome 
editing plasmids. Viral packaging size limitations mean that clinically-relevant viruses 
such as AAV cannot be used to deliver genome editing reagents. While lipofection has 
been used by our group and others to successfully correct disease-causing mutations in 
iPSCs, these reagents are not cGMP compatible. Further, given that the transfection 
efficiency associated with lipofection and electroporation drops with increasing construct 
size, the best transfection efficiencies we can currently reach are still less than 1%. 
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Recently, our group demonstrated a novel transfection technology that uses mechanical 
perturbations to induce convective delivery of macromolecules to cells [1], [2]. This 
technique does not require the use of any chemical reagents and is cGMP compatible. 
Further, given that payloads are delivered to cells using a convective mechanism, there is 
no substantial dependence of delivery efficiency on payload size, meaning that large 
constructs can be delivered with very high efficiency. 
In this chapter, I will detail our recent work on applying this technology for the repair of 
disease-causing mutations in patient-derived iPSCs. While our initial results are promising, 
we believe that for this technique to reach its full potential it will be necessary to integrate 
this transfection platform into multistage microfluidic devices to overcome the high degree 
of size heterogeneity discovered in patient-derived iPSC populations. 
5.3 Methods 
5.3.1 Atomic force microscopy 
Measurements of the viscous relaxation of individual cells during repeated compressions 
were performed using an MFP-3D AFM (Asylum Research) in concert with an inverted 
optical microscope (Nikon Ti) to optically align the AFM probe with the center of each 
cell. The probes used in this study were MLCT-O10-D probes with a nominal spring 
constant of 0.03 N/m. The AFM cantilever interacted with the cells via a 15-μm diameter 
PMMA microsphere. Cantilever calibration was performed using the thermal vibration 
method against a glass surface. K562 cells in culture media were adhered to the surface of 
a glass Fluorodish using Cell-Tak (Corning). The indentation depth was chosen to be 10 μm 
to simulate the strain imposed by a 5-μm gap in a microfluidic channel. The cell relaxation 
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constant was extracted from the decay of viscous forces acting on the probe while 
maintaining constant indentation for 2 s after compression. 
5.3.2 iPSC culture and maintenance 
iPSCs generated from human dermal fibroblasts via infection with non-integrating Sendai 
viruses designed to drive expression of the four transcription factors OCT4, SOX2, KLF4, 
and c-MYC (Invitrogen/Thermo Fisher Scientific, CytoTune-iPS Reprogramming Kit) 
were used in this study [12]. Following generation, clonal expansion and characterization, 
iPSCs were maintained on either Matrigel (10ug/mL, BD Bioscience) coated culture plates 
in mTseR1™ media (Stem Cell Technologies) or hLaminin521-coated (10ug/mL, 
BioLamina) culture plates in Human Essential 8™ (E8) media (Invitrogen/Thermo Fisher 
Scientific). Cells were passaged using ReLeSR™ (Stem Cell Technologies) as per the 
manufacturer’s protocol. 
5.3.3 Microscopic analysis 
To evaluate culture confluence and cellular morphology, iPSC cultures were imaged via 
phase microscopy using an EVOS XL digital microscope. 
5.3.4 iPSC size analysis 
iPSC cells were first detached from their culture vessels and dissociated using ReLeSR™ 
(Stem Cell Technologies) as per the manufacturers protocol. Cells were then collected via 
centrifugation and resuspended in ISOTON II diluent (Beckman Coulter) for analysis. 
Before each day of measurements a size standard (Coulter CC Size Standard L10, Beckman 
Coulter) was used to calibrate the coulter counter used for analysis (Z2, Beckman Coulter) 
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as per the instrument documentation. After calibration, each sample was measured three 
times and the instrument was flushed between each sample. The instrument was 
programmed to only record objects between 6 and 25 microns in size, and population 
metrics such as median size and size standard deviation were recorded after each 
measurement. 
5.4 Results 
Like many microfluidic technologies, the performance of our transfection platform is 
dependent on the careful selection of device geometry and operating conditions. In our 
approach, cells are perturbed by forcing them to pass through periodic constrictions that 
cause them to alternately lose volume under the constrictions and then regain the lost 
volume in between [1], [2]. We believe that this volume exchange with the surrounding 
buffer is what leads to the convective transport of macromolecules across the cell 
membrane. Therefore, the most important parameters to optimize when using our technique 
are the size of the constrictions and the flow rate. In order to illustrate how these parameters 
can affect transfection efficiency it is helpful to imagine extreme cases. For instance, if the 
constrictions are so large that the cells do not have to deform in order to pass through them, 
no volume exchange will occur and thus no transfection will be observed. Conversely, if 
the constrictions are too small, the cells will either be destroyed or the device will clog, 
resulting in a failed procedure. One can also imagine extremes in flow rate. If the flow rate 
is very low, the hydrodynamic force acting on the cells will not be large enough to force 
them through the constrictions, resulting in no transfection. On the other hand, if the flow 
rate is very high, cells will not have enough time to recover their lost volume in between 
the constrictions, reducing the efficacy of the technique. The goal in optimizing these 
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parameters for a given application is to find a pair of constriction size and flow rate where 
the cells are adequately perturbed to effect transfection, do not clog the device, and have 
sufficient time between constrictions to recover any volume lost while compressed. 
To aid in the design of convective microfluidic transfection devices for delivery of 
macromolecules to iPSCs, we designed a simple mechanistic model of how we hypothesize 
delivery occurs in these devices. As shown in Figure 18a, we assumed that cells enter the 
device at some initial volume V0, which reduces to Vc when under a constriction. We 
further assumed that after being compressed, the cell volume would increase between the 
ridges, asymptotically approaching V0 at a rate governed by the time constant τ. Initially, 
this time constant was the only free parameter in the model, given that V0 was measured 
experimentally and Vc was estimated by assuming that cells under a ridge have the shape 
of a truncated sphere with radius equal to the undeformed radius of the cells and height set 
by the constriction size. We then assumed that macromolecule concentration in the 
surrounding buffer was constant, that the interior of the cells were well mixed, and that 
transport across the membrane was due to pure convection, allowing us to use our volume 
change model to predict intracellular macromolecule concentration.  
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Figure 18. Mechanistic model of convective microfluidic delivery of macromolecules 
to cells. (a) Model overview. (b) Best model fit assuming variable cell relaxation rate or 
constant cell relaxation rate plotted against experimental data for fluorescent intensity vs. 
number of constrictions. (c) Best model fit plotted against experimental data for fluorescent 
intensity vs. macromolecule concentration. (d) Best model fit plotted against experimental 
data for fluorescent intensity vs. constriction size. (e) Time constant governing cell 
relaxation vs. compression number. This result shows that K562 cells relax more quickly 
after repeated compressions. 
As shown in Figure 18b, our initial model, which assumes that cell relaxation rate is 
constant after each constriction, did not fit well to our data, causing us to suspect that cell 
relaxation rate may in fact change after repeated compressions. To test this hypothesis, we 
proceeded to use an atomic force microscope to repeatedly compress K562 cells and 
measure the relaxation rate of the cell after each compression. As shown in Figure 18e, this 
experiment found that K562 cells relax more quickly after repeated compressions, perhaps 
due to disruption of the cytoskeleton or the formation of pores in the cell membrane. While 
the rate of compression in our AFM experiment was orders of magnitude slower than that 
which occurs in our microfluidic device, it seemed plausible that similar behavior could be 
happening in our microfluidic device. We then replaced our single free parameter, τ with 
three parameters: τ0, the rate of cell relaxation after being compressed once, τ∞, the rate of 
cell relaxation after many compressions, and ζ, the rate constant governing how cell 
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relaxation rate asymptotically approaches τ∞ from τ0. As shown in Figure 18, this model fit 
well to our experimental data for delivery of fluorescent dextran to K562s as a function of 
number of constrictions, macromolecule concentration and constriction size. 
In an attempt to find such an optimal device geometry and operating condition for the 
transfection of iPSCs, we attempted to deliver large, multicistronic gene editing constructs 
to iPSCs using devices with several different constriction sizes at a variety of flow rates. 
While we were able to demonstrate successful delivery to iPSCs, as shown in Figure 19, 
the efficiency of our platform was no better than lipofectamine. 
 
Figure 19. Microfluidic transfection as compared to lipofectamine. While we were able 
to use our microfluidic platform to deliver large plasmids to iPSCs, transfection efficiency 
was no better than lipofectamine. Scale bar is 400 microns. 
To investigate what might be causing our lower than expected transfection efficiencies, we 
performed extensive characterization of iPSC size while varying many key conditions such 
as patient of origin, plating density (see Figure 20), choice of adhesion protein, cell culture 
media and time in suspension. Overall, these results were very consistent. As shown in 
Figure 21, we saw no substantial difference in the size of iPSCs derived from different 
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doners, which leads us to believe that a system capable of transfecting cells from one 
patient would constitute a general-use tool capable of working across any iPSCs generated 
using standard protocols. Further, as shown in Figure 22 there seems to be little effect of 
culture conditions on the size of iPSCs, provided the cultures are not allowed to become 
massively over-confluent. Specifically we did not find any marked difference in the size of 
iPSCs cultured on Lamin-coated dishes in E8 media as compared to those cultured on 
Matrigel-coated dishes in mTseR1 media. Finally, as displayed in Figure 23, we showed 
that the amount of time cells are left in suspension also does not have an effect on cell size, 
implying that overall processing time does not need to be tightly controlled to allow for 
successful transfection. Unfortunately, while the median cell size across our measured 
conditions was very consistent, significant amounts of heterogeneity in terms of size was 
observed across all of the iPSC populations measured. Standard deviations in size of the 
populations measured ranged from ~2.5 to ~3.3 microns, corresponding to ~20% of the 
median cell sizes measured. For comparison, the standard deviation of T cell size in most 
humans is reported to be ~10% of the mean cell diameter [169]. 
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Figure 20. iPSC Morphology at various cell densities. Scale bar is 1000 microns for 4x 
images, 200 microns for 10x images. 
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Figure 21. Measured iPSC size for iPSCs derived from several different patients. No 
substantial difference in median cell size was observed between iPSCs derived from 5 
different patients. Error bars represent the standard deviation of size within each sample. 
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Figure 22. iPSC size at various culture conditions. The size of iPSCs grown on laminin 
and Matrigel were measured at several different culture densities. While no substantial 
trends were observed, there was significant size heterogeneity at all measured conditions. 
Error bars represent the standard deviation of size within each sample. 
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Figure 23. iPSC size immediately after dissociation and after 3 hours in suspension. 
No substantial change in size was observed after allowing cells to rest in suspension for 3 
hours. This indicates that processing time should not have a large impact on device 
performance. Error bars represent the standard deviation of size within each sample. 
This size heterogeneity appears to be a property of iPSCs and may be due to the way in 
which they grow in vitro. iPSCs generally grow in colonies, and as shown in Figure 24, 
cells growing at the edges of the colonies seem to be larger than their companions in the 
center. This suggests a naïve method of reducing heterogeneity, simply expanding the cells 
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until they are fully confluent (removing the distinction between cells on the edge of a 
colony and those in the center). Interestingly, we did find that when cultures were allowed 
to become massively overconfluent the average cell size and standard deviation from the 
mean did decrease slightly. Unfortunately, as overconfluence of iPSC cultures often results 
in spontaneous differentiation and a loss of potency, this should be avoided. 
 
Figure 24. iPSC morphology at the center and edge of iPSC colonies. iPSCs in the 
center of colonies (left) appear to be smaller and more uniform in size than those at the 
edges of colonies (right). Scale bars are 400 microns. 
The observed heterogeneity in terms of size presents a significant obstacle to our goal of 
microfluidic enhancement of transfection. As stated above, the performance of this 
transfection platform depends on careful tuning of device geometry to cause significant 
compression of cells without clogging, a task that is made very difficult if there is 
significant variation in cell size. For example, a device that could perform perfectly on cells 
close to the mean size in a population may become clogged due to larger cells present in 
the mixture and may not compress smaller cells enough to cause transfection. 
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To address this issue, we envision a modification of our device that will integrate a size-
based sorter upstream of the transfection platform. We hypothesize that by splitting a 
heterogeneous iPSC population into subpopulations of more uniform size, we will 
dramatically improve the performance of our device and achieve transfection efficiencies 
significantly higher than those that are possible using existing approaches, such as 
lipofectamine. 
5.5 Conclusions 
In order to enable the development of autologous cell therapies for degenerative inherited 
conditions, transfection platforms are needed that are safe and capable of delivering large 
gene editing constructs to the interior of iPSCs. To meet this need, we propose adapting a 
microfluidic transfection technology developed in our group to iPSC transfection. 
Although we successfully used this platform to deliver large CRISPR/HDR constructs to 
patient-derived iPSCs, our progress has been hampered due to the large degree of size 
heterogeneity present in these cell lines. To address this issue, we propose a multistage 
microfluidic device capable of first presorting a heterogeneous iPSC mixture into 
subpopulations that are relatively homogeneous in size, which can then be processed 
efficiently using our microfluidic sorting platform. We believe that when complete, this 
multistage device will be capable of delivering large constructs to iPSCs much more 
efficiently than current techniques and in a manner that is compliant with cGMP. This will 
have the potential to increase the utility and safety of current cell manufacturing pipelines 
and make the production of patient-derived cell therapies safer, simpler and less expensive. 
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CHAPTER 6. CONCLUSIONS 
Microfluidic cell processing has the potential to revolutionize the areas of personalized and 
regenerative medicine. In this thesis, I have shown how microfluidic cell sorting and 
transfection could increase the safety and potency of manufactured cell therapies while 
simultaneously making cell manufacturing pipelines simpler and cheaper to operate. I have 
further shown that microfluidic cell sorting has the promise to increase the efficacy of 
modern personalized medicine techniques by purifying cancer cells in noninvasively 
obtained liquid biopsies. In this chapter, I will summarize the contributions I have made 
towards applying microfluidic cell processing for personalized and regenerative medicine 
in the pursuit of three specific aims. 
6.1 Aim 1: Label-free microfluidic enrichment of cancer cells from non-cancer cells 
in ascites 
6.1.1 Summary 
Personalized medicine promises to revolutionize the treatment of cancers by using 
functional and molecular characterization of a patient’s own cancer cells to inform 
treatment decisions. While these approaches show great promise, it is currently difficult to 
obtain pure populations of a patient’s cancer cells, an issue that must be solved before 
personalized medicine techniques can reach their full utility. While cells from a patient’s 
primary tumor can be collected via biopsy, these operations are often quite invasive. In 
order to avoid performing invasive procedures on cancer patients who are often in poor 
health, recent approaches have explored the use of ‘liquid biopsies’, in which liquid 
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samples containing metastatic cancer cells (such as a patient’s blood or abdominal fluid) 
are taken from patients in less invasive procedures. Unfortunately, these liquid biopsies do 
not result in pure populations of cancer cells. Instead, the malignant cells which are desired 
for functional and molecular characterization are generally mixed with contaminating 
blood and immune cells, which should be removed in order to increase the sensitivity of 
downstream assays. While many high throughput cell sorting technologies such as MACS 
and FACS have been commercialized, the dependence of these ‘gold-standard’ approaches 
on the presence of unique surface markers on cells of interest limit their utility for cancer 
applications. Given that every patient’s cancer is unique, it is very difficult to depend on 
the presence of a specific marker to perform sorting using antibody-based techniques. To 
address this issue, we used a label-free microfluidic sorting platform to isolate cancer cells 
based on their size and stiffness, which has been shown to be a reliable marker for 
malignancy in many cancers. After exploring the feasibility of our technique using 
representative ovarian cancer cell lines we proceeded to isolate cancer cells from liquid 
biopsies taken from ovarian cancer patients. Analysis of our sorted populations using both 
immunocytochemistry and next generation sequencing techniques showed that our 
platform successfully enriched cancer cells from the mixed populations present in these 
liquid biopsies without relying on specific cell surface markers. These results show the 
great promise that our platform, and microfluidic label-free sorting in general, has for 





6.1.2 Future directions 
While our results for isolation of metastatic ovarian cancer cells from patient ascites were 
quite promising, there is work remaining before our sorting platform will be ready for 
clinical applications. First, experiments should be performed to determine how the 
sensitivity of personalized medicine assays change with increasing sample purity to 
determine the absolute purity that is required for these applications. Next, the purity of the 
samples generated using our platform should be quantified via histology to get a concrete 
number for the purity that is currently being achieved using our device. If higher purity is 
required, further optimization of the device could be performed, or a complete redesign 
could be undertaken. Given recent interest in the importance of circulating cancer cell 
clusters in metastasis, this redesign could focus on size-based sorting, which could be 
capable of sorting metastatic cancer cell clusters from single cells. 
6.2 Specific Aim 2: Label-free microfluidic enrichment of photoreceptor cells 
6.2.1 Summary 
Induced pluripotent stem cell (iPSC) derived autologous cell therapies are a promising 
treatment for patients with a variety of conditions, including inherited degenerative 
blindness. In these treatment approaches, patient-derived iPSCs are generated from 
fibroblasts harvested from a patient via a skin biopsy. These iPSCs can then be 
differentiated into cells capable of regenerating tissue a patient has lost due to injury or 
disease. In the case of inherited degenerative blindness, our group and others are 
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developing pipelines for the manufacture of patient-derived photoreceptors which we hope 
will be capable of restoring a patient’s vision after transplant. Unfortunately, current iPSC 
differentiation protocols do not result in pure populations of therapeutically relevant cells. 
Retinal differentiation protocols used for the production of photoreceptors result in a mixed 
population of many cell types present in the mature human retina, such as retinal pigment 
epithelium (RPE), glial, and photoreceptor cells. In order to increase the potency of cell 
therapies produced using these pipelines, a cell sorting approach is required to purify cells 
desired for transplant from other contaminating cells. 
While very selective, gold-standard approaches such as FACS and MACS are not well 
suited to this application. Conjugation of animal-derived antibodies to cells destined for 
transplant into patients poses significant safety risks, and the use of expensive FACS 
sorters to isolate cells destined for transplant into multiple patients increases the risk of 
contaminating cells manufactured for one patient with those intended for others. Label-free 
microfluidic sorting systems can be implemented as single-use, disposable chips which 
drastically reduce the risk of product contamination and can be operated without the use of 
reagents, such as monoclonal antibodies, which could compromise the safety and increase 
the regulatory burden associated with these treatments. 
To demonstrate how label-free microfluidic sorting systems could be used to increase the 
potency and safety of iPSC-derived autologous cell therapies, we applied our microfluidic 
sorting platform to the isolation of photoreceptors from the mixture of cell types found in 
the human retina. After performing mechanical characterization of representative cell lines 
to show that target photoreceptors and contaminating cells are mechanically distinct and 
sortable using our approach, we proceeded to isolate photoreceptors from dissociated 
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whole human retina. We then examined the gene expression profiles of our sorted 
populations, which showed that our device was capable of enriching photoreceptors from 
the mixture of cell types present in whole human retina. We believe that this result indicates 
that label-free microfluidic sorting should be capable of isolating photoreceptors from 
contaminating cells produced during iPSC differentiation protocols, thereby increasing the 
potency and safety of the resulting cell therapy. 
6.2.2 Future directions 
While our results showing enrichment of cone photoreceptors from dissociated post-
mortem human retina indicate that our platform should be capable of isolating 
photoreceptors from patient iPSC derived retinal organoids, our next step is to prove that 
it is. The first step in this process will be to perform detailed size and mechanical 
characterization of the populations present in mature iPSC derived retinal organoids, after 
which our device will need to be redesigned and reoptimized for this application. 
6.3 Specific Aim 3: Use microfluidics to deliver large functional constructs to 
patient derived iPSCs in a one-step mechanical process 
6.3.1 Summary 
When manufacturing cell therapies for the treatment of inherited conditions, it is likely that 
any disease-causing mutations will need to be corrected in patient-derived iPSCs before 
differentiating them into the cell types relevant for therapy. In practice, this means that 
technologies capable of delivering large gene editing constructs at high efficiency are 
needed. While many cell transfection technologies such as electroporation, lipofection and 
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viral transduction have been developed previously, none of them are ideal for correcting 
mutations in genes in patient-derived iPSCs. Packaging size limitations make it impossible 
to use clinically-relevant viruses for this application, and while both lipofectamine and 
electroporation have been used to correct mutations in iPSCs previously, both suffer from 
very low transfection efficiencies when delivering large constructs. 
Recently, our group developed a reagent-free microfluidic transfection platform capable of 
delivering large payloads to cells using convective transport. As this technology 
accomplishes delivery using an active (convective) transport mechanism, it is capable of 
delivering very large macromolecules to cells with very high efficiency, making it ideal for 
use in this application. 
While we demonstrated transfection with efficiencies comparable to lipofectamine, we 
believe that this is not the highest possible transfection efficiency achievable with our 
platform. One drawback of this microfluidic transfection platform is that it does not 
perform well when used to process cell populations that are heterogeneous in terms of size. 
To determine if this would be an issue in our case, we performed extensive characterization 
of how iPSC size changes with different culture conditions, such as plating density and 
choice of adhesion protein. This characterization revealed that there exists significant size 
heterogeneity in iPSC populations even when these parameters are controlled for. 
6.3.2 Future directions 
In order to address the previously unreported size heterogeneity of iPSCs, our next step is 
the design of a multistage microfluidic device capable of splitting heterogeneous iPSC 
populations into homogeneous subpopulations through size based sorting upstream of 
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transfection. Each of these subpopulations could then be transfected using channels 
optimized for that population. We believe that such a device will be capable of transfecting 
iPSCs at very high efficiencies, simplifying iPSC manufacturing pipelines for regenerative 
medicine applications. 
6.4 Summary 
In this thesis, I have demonstrated how microfluidic cell processing can be used to improve 
current methodologies for both personalized and regenerative medicine. In aim one, I 
showed how label-free microfluidic cell sorting can be used to improve personalized 
medicine workflows by enabling isolation of metastatic cancer cells from liquid biopsies 
without relying on antibody labels. In aim two, I demonstrate that microfluidic cell sorting 
can be used to isolate photoreceptors from other retinal cell populations to improve the 
safety and potency of cell therapies for inherited degenerative blindness. Finally, in aim 
three, I demonstrate successful delivery of a large multicistronic CRISPR construct to 
patient derived iPSCs at efficiencies comparable to lipofectamine, a standard in the field. 
In addition, I performed the first in depth characterization of iPSC cell size, with the end 
goal of designing a new microfluidic platform capable of enhancing the efficiency with 
which large gene editing constructs can be delivered to patient-derived iPSCs. Taken as a 
whole, this work demonstrates the central role microfluidic cell processing will play in 
personalized and regenerative therapies for cancer, inherited blindness and other 
conditions. 
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APPENDIX A. OPTIMIZATION OF MICROFLUIDIC SORTING 
DEVICES 
Currently, our microfluidic sorting platform must be reoptimized for every application. 
While this procedure is laborious and requires a decent amount of intuition, it can be 
approached in a semi-systematic way, as shown in Figure X. The crucial, first step in this 
process is exhaustive characterization of the size and mechanics of the populations to be 
sorted to ensure that there are differences to exploit. For the work contained in this thesis, 
I performed mechanical characterization using atomic force microscopy (AFM) and size 
characterization using light microscopy and a coulter counter. While light microscopy is 
an acceptable method for measuring cell size, coulter counters are preferable, given that 
they are much higher throughput while being highly quantitative with respect to size. 
 
Figure 25. Optimization scheme for label-free microfluidic cell sorting. My 
optimization workflow starts with detailed size and mechanical characterization of cell 
populations to be sorted. Next, detailed trajectory analysis should be performed while 
varying device geometry and flow rates. The operation conditions that result in the biggest 
difference in characteristic trajectory of cells to be sorted can then be used to sort the cells 
of interest. 
After performing characterization of the populations to be sorted, devices with a variety of 
ridge gaps should be fabricated. A good initial guess for an appropriate constriction size is 
50-75% of the diameter of the largest cells to be sorted. These devices should then be tested 
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to find a constriction size/flow rate combination that results in qualitative differences in 
behavior between large/stiff and small/soft populations. Once this rough optimization has 
been completed, detailed trajectory information for each population to be sorted should be 
captured using high speed microscopy. This trajectory information should be captured 
while varying flow rate, ridge spacing and constriction size. Analysis of this data will allow 
the operator to discover the optimum device and flow rate which results in the largest 
difference between the characteristic trajectories of the populations to be sorted. 
Finally, a sort should be attempted. The relative flow rates of the cell and sheath inlets 
should then be tuned (while keeping the total flow rate constant) to accomplish three goals. 
First, the cell stream should be well focused, so that each cell contacts the first ridge at the 
same point. Second, the total cell concentration should be controlled to minimize 
interactions between cells within the device, which can lead to poor sorting or clogs. 
Lowering this cell concentration, however, directly reduces throughput so it should only 
be reduced when necessary. Third, the relative flow rate of the two sheath inlets should be 





APPENDIX B.  DESIGN IMPROVEMENTS FOR 
TRANSFECTION DEVICES 
Over the course of the work contained in this thesis, I made two key contributions to the 
design of our transfection devices. First, I designed the symmetric constrictions of our 
transfection platform, illustrated in Figure 26. In our initial exploration of convective 
macromolecule delivery, we simply used our sorting platform to perform the compressions 
required to mediate transfection. However, the asymmetric design of our sorting platform 
had some disadvantages for transfection applications. Most importantly, our sorting 
platform is designed to cause cells to move laterally in the device, which could cause cells 
to exit the active region of the device before being compressed by each ridge. The 
symmetric design is intended to direct relatively small/soft cells towards the center of the 
channel, while directing large aggregates, which interfere with the operation of our device, 
out of the active region. This ability to redirect cells to the center of our device’s active 
region also decreases the reliance of our device on precise cell focusing, which allowed us 
to remove the sheath inlets used in early devices. Removal of the sheath inlets simplified 
operation of the device and reduced consumption of expensive reagents. 
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Figure 26. Symmetric constrictions for transfection devices. These symmetric 
constrictions are designed to focus single cells into the center of the transfection channel, 
while directing aggregates to the edges of the device. 
While our redesigned transfection devices can be operated without any cell focusing, 
sheathless focusing would allow operators to ensure that every cell is successfully 
delivered to the active region of the device without wasting reagents by using sheaths. To 
this end, I introduced hydrodynamic focusing channels, illustrated in Figure X, at the inlets 
of our devices. These channels tend to concentrate cells with similar size into a single 
streamline, directing cells to the active region of our device without using sheaths [142]. 
Use of these focusing channels is now standard practice in our group. 
 
Figure 27. Hydrodynamic focusing channels for sheathless operation of transfection 
devices. These channels tend to focus cells of similar size into a single streamline, allowing 
cells to be directed into the active area of our device without using sheath inlets. 
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